Original Article
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
N Engl J Med 2006; 355:2071-2084November 16, 2006
- Abstract
Background
Whether correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes is not established.
Methods
We randomly assigned 603 patients with an estimated glomerular filtration rate (GFR) of 15.0 to 35.0 ml per minute per 1.73 m2 of body-surface area and mild-to-moderate anemia (hemoglobin level, 11.0 to 12.5 g per deciliter) to a target hemoglobin value in the normal range (13.0 to 15.0 g per deciliter, group 1) or the subnormal range (10.5 to 11.5 g per deciliter, group 2). Subcutaneous erythropoietin (epoetin beta) was initiated at randomization (group 1) or only after the hemoglobin level fell below 10.5 g per deciliter (group 2). The primary end point was a composite of eight cardiovascular events; secondary end points included left ventricular mass index, quality-of-life scores, and the progression of chronic kidney disease.
Results
During the 3-year study, complete correction of anemia did not affect the likelihood of a first cardiovascular event (58 events in group 1 vs. 47 events in group 2; hazard ratio, 0.78; 95% confidence interval, 0.53 to 1.14; P=0.20). Left ventricular mass index remained stable in both groups. The mean estimated GFR was 24.9 ml per minute in group 1 and 24.2 ml per minute in group 2 at baseline and decreased by 3.6 and 3.1 ml per minute per year, respectively (P=0.40). Dialysis was required in more patients in group 1 than in group 2 (127 vs. 111, P=0.03). General health and physical function improved significantly (P=0.003 and P<0.001, respectively, in group 1, as compared with group 2). There was no significant difference in the combined incidence of adverse events between the two groups, but hypertensive episodes and headaches were more prevalent in group 1.
Conclusions
In patients with chronic kidney disease, early complete correction of anemia does not reduce the risk of cardiovascular events. (ClinicalTrials.gov number, NCT00321919.)
Media in This Article
Figure 1
Enrollment, Randomization, and Study Completion.Figure 2
Median Hemoglobin Levels in the Intention-to-Treat Population during the Study.Article Activity
- Article
Anemia is a common complication of chronic kidney disease. However, the optimal target hemoglobin levels for patients with various stages of chronic kidney disease are unclear. Anemia is strongly predictive of complications and death from cardiovascular causes in patients with chronic kidney disease.1 Observational data indicate that correction of anemia is associated with improved outcomes.1-8 However, the normalization of hemoglobin in prospective trials involving patients receiving hemodialysis did not improve left ventricular indexes or decrease the risk of death.9-11
Among patients with chronic kidney disease, the effect of correction of anemia may differ between those who require dialysis and those who do not. The latter group generally has less advanced cardiovascular disease and no risk of dialysis-related increases in hemoglobin or vascular access thrombosis. Several observational and small interventional studies of patients with chronic kidney disease who were not receiving dialysis reported an inverse relation between hemoglobin levels and cardiovascular outcomes.12-14 However, two recent randomized studies did not confirm that left ventricular mass decreased in response to complete correction of anemia.15,16
In the Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) trial, we tested the hypothesis that complete correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes as compared with partial correction of anemia.
Methods
The trial was designed, implemented, and overseen by the steering committee together with representatives of the sponsor, F. Hoffmann–La Roche. The sponsor was responsible for monitoring the centers and the data collection and for checking the quality of the data. The sponsor also conducted all statistical analyses and holds the data. The members of the steering committee had access to all the study data, which they analyzed in close collaboration with the sponsor. The initial manuscript was prepared by Drs. Drüeke and Scherhag and underwent several revisions with contributions from all coauthors. An independent data and safety monitoring board (see the Appendix) reviewed the data regularly. All cardiovascular end points were reviewed and adjudicated by an end-point committee (see the Appendix) whose members were unaware of the group assignments of the patients.
Study Population
Eligible patients were enrolled at 94 centers in 22 countries. The study began in July 2000 and ended in November 2004, 2 years after enrollment of the last patient. Patients older than 18 years were eligible for inclusion if they had mild-to-moderate chronic anemia (hemoglobin level, 11.0 to 12.5 g per deciliter) related to their chronic kidney disease, an estimated glomerular filtration rate (GFR) of 15.0 to 35.0 ml per minute per 1.73 m2 of body-surface area (calculated with the use of the Cockcroft–Gault formula), and a blood pressure of 170/95 mm Hg or less. The use of antihypertensive treatment to achieve the target blood pressure was encouraged. Major exclusion criteria were an anticipated need for renal replacement therapy within 6 months, advanced cardiovascular disease (as defined by a diagnosis of clinically significant valvular disease, congestive heart failure, myocardial infarction, unstable angina, or stroke within the preceding 3 months), nonrenal causes of anemia, receipt of blood transfusions within the preceding 3 months, a serum ferritin level of less than 50 ng per milliliter, a C-reactive protein level exceeding 15 mg per liter, and previous treatment with erythropoietin.
All patients provided written informed consent. The study protocol was approved by local ethics committees. The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.
Study Protocol
This was an open-label, randomized, two-group study with a parallel-group design. The primary objective was to investigate the effect on complications from cardiovascular causes of early treatment with subcutaneous erythropoietin (epoetin beta [NeoRecormon, F. Hoffmann–La Roche]) to normalize hemoglobin values (target level, 13.0 to 15.0 g per deciliter; group 1), as compared with treatment to partially correct anemia (target level, 10.5 to 11.5 g per deciliter; group 2). Secondary study objectives included the investigation of the effects of these treatments on the left ventricular mass index, the progression of chronic kidney disease, and the quality of life. The study design and other details of the study protocol have been published elsewhere.17
Patients were randomly assigned (at a 1:1 ratio) to receive either immediate treatment with epoetin beta in order to reach a target hemoglobin level of 13.0 to 15.0 g per deciliter (group 1) or treatment with epoetin beta only after the hemoglobin level had decreased to less than 10.5 g per deciliter (group 2). Patients in group 2 were to maintain a hemoglobin level of 10.5 to 11.5 g per deciliter. The starting dose of epoetin beta was 2000 IU, and the treatment was administered subcutaneously once weekly with the use of an automatic pen device (Reco-Pen). Dose adjustments to achieve the target hemoglobin level were permitted. The dose was reviewed every 4 weeks; if the hemoglobin level had increased by less than 0.5 g per deciliter, the dose was increased by 25 to 50%, and if the level had increased by more than 1.0 g per deciliter, the dose was reduced by 25 to 50%. Iron supplementation (intravenous or oral) was recommended at the discretion of the investigators, who were encouraged to follow current clinical practice guidelines. Routine clinical visits were scheduled every 2 weeks during the hemoglobin correction phase (lasting 3 months) and every 3 months thereafter. Study end points and adverse events were continuously monitored. Follow-up of clinical events continued until the end of the study for all patients, including those undergoing dialysis.
Study End Points
The primary efficacy end point was the time to a first cardiovascular event, including sudden death, myocardial infarction, acute heart failure, stroke, transient ischemic attack, angina pectoris resulting in hospitalization for 24 hours or more or prolongation of hospitalization, complication of peripheral vascular disease (amputation or necrosis), or cardiac arrhythmia resulting in hospitalization for 24 hours or more.
Secondary efficacy end points included death from any cause; death from cardiovascular causes; congestive heart failure (according to New York Heart Association [NYHA] class); the need for cardiovascular intervention; hospitalization for any cause; hospitalization for cardiovascular reasons for 24 hours or more or prolongation of hospitalization; changes in left ventricular mass index, left ventricular volume, and left ventricular fractional shortening; time to initiation of renal replacement therapy; changes in nutritional status, as reflected by the body-mass index (the weight in kilograms divided by the square of the height in meters), serum albumin level, and C-reactive protein level; changes in the quality of life, according to the score for the 36-item Medical Outcomes Study Short-Form Health Survey (SF-36), on which scores for each subscale range from 0 to 100, with higher scores indicating better health18; changes in hemoglobin levels; changes in the weekly epoetin dose; the need for dialysis; the need for transfusion; and decrease in the estimated GFR, which was estimated with the use of the Cockcroft–Gault equation and the simplified Modification of Diet in Renal Disease IV study equation (see the glossary in the Supplementary Appendix, available with the full text of this article at www.nejm.org).
Echocardiographic Assessment
Standard echocardiography was performed according to the guidelines of the American Society of Echocardiography19,20 at baseline and then annually or at the initiation of dialysis. The results were interpreted in an independent echocardiographic core laboratory by staff members who were unaware of the patient's target hemoglobin range. Left ventricular hypertrophy was defined as a left ventricular mass index greater than 100 g per square meter of body-surface area in women and greater than 130 g per square meter in men.
Statistical Analysis
We calculated that 600 patients would need to be enrolled for the study to have a statistical power of 80% to detect a significant difference in the primary end point between the two groups, given an annual incidence of the primary end point of 15% among patients in group 221 and a significance level of 5% with the use of a two-sided log-rank test. Randomization was performed centrally with the use of a dynamic randomization method including a random element of 30% and stratification according to study site, previous cardiovascular risk, and estimated GFR. With a recruitment period of 2 years and a follow-up period of another 2 years, we calculated that 200 events would have to occur in order to show, with a statistical power of 80%, a reduction in the hazard ratio for a first cardiovascular event by one third. The study followed a sequential design, with interim analyses adjusted for multiplicity with the use of an O'Brien–Fleming spending function. The study was scheduled to end, at the latest, 2 years after the final patient had undergone randomization or after 200 events had occurred.
All analyses followed the intention-to-treat principle. The primary end point — the time to the first cardiovascular event — was adjusted for the presence or absence of underlying cardiovascular disease at baseline and analyzed with the use of the log-rank test. A Cox proportional-hazards model was used to estimate the relative risk (hazard ratio) and the corresponding 95% confidence interval (CI). The times to events were expressed as Kaplan–Meier curves. A similar method was used to analyze secondary end points, time to death from cardiovascular causes, time to death from any cause, and time to dialysis. Analysis of covariance was used for secondary efficacy end points that were continuous variables, with baseline value and treatment as covariates. Data are reported as means ±SD, unless otherwise indicated.
Results
Patients and Baseline Characteristics
We enrolled 605 patients, but 2 were excluded from the analysis because they were from a center that was closed owing to failure to adhere to Good Clinical Practice guidelines (Figure 1Figure 1
Enrollment, Randomization, and Study Completion.). The intention-to-treat population therefore included 603 patients (301 patients in group 1 and 302 patients in group 2); of these, 476 (79%) completed the study. The mean duration of observation for the primary end point was approximately 3 years (1044 days for group 1 and 1092 days for group 2, P=0.42).Except for a small difference in the sex ratio, the baseline characteristics of the patients were similar in the two groups (Table 1Table 1
Demographic and Baseline Characteristics.). Seventy-five patients (25%) withdrew prematurely from group 1, and 52 (17%) from group 2 (P=0.02). The major reasons for withdrawal were death (21 patients in group 1 and 17 in group 2; P=0.60), adverse events (17 and 10 patients, respectively; P=0.20), and withdrawal of consent or lack of cooperation (23 and 14 patients, respectively; P=0.15).Treatment of Anemia
At baseline, the mean hemoglobin level was 11.6±0.6 g per deciliter in both groups. In group 1, 98% of patients received at least one dose of epoetin beta. In group 2, 32% of patients had received epoetin beta at year 1, 52% at year 2, and 76% at the end of the study. Overall, an average of 67% of patients in group 2 received epoetin beta at any time during the study. The difference in the median hemoglobin level between the two groups was 1.9 g per deciliter at year 1, 1.7 g per deciliter at year 2, and 1.5 g per deciliter at the end of the study (Figure 2Figure 2
Median Hemoglobin Levels in the Intention-to-Treat Population during the Study.). The median weekly epoetin dose was 5000 IU (range, 3000 to 8000) in group 1 and 2000 IU (range, 1000 to 3000) in group 2. In group 1, 62% of patients received at least one dose of oral iron, as did 60% of those in group 2; 52% of patients in group 1 and 42% of those in group 2 received at least one dose of intravenous iron. Twenty-six patients in group 1 received a blood transfusion, as did 33 patients in group 2.Control of Blood Pressure
Normalization of the hemoglobin level was not associated with a long-term increase in mean blood pressure in group 1 (at baseline, systolic blood pressure was 139±17 mm Hg and diastolic blood pressure was 79±10 mm Hg; at the end of the study, systolic blood pressure was 136±21 mm Hg and diastolic blood pressure was 79±11 mm Hg). The mean blood pressure values in group 1 did not differ significantly from those in group 2 (group 2: at baseline, systolic blood pressure was 139±16 mm Hg and diastolic blood pressure was 80±9 mm Hg; at the end of the study, systolic blood pressure was 135±19 mm Hg and diastolic blood pressure was 77±12 mm Hg). However, hypertension (defined as a systolic blood pressure of more than 160 mm Hg) was reported as an adverse event in more patients in group 1 than in group 2 (Table 2Table 2
Summary of the Most Frequent Adverse Events and Other Relevant Adverse Events.). Despite a higher rate of beta-blocker use in group 1, there was no significant difference between groups in the numbers of patients prescribed at least one antihypertensive agent at baseline (Table 1). During the study, the number of prescriptions for angiotensin II–receptor blockers, beta-blockers, and calcium-channel blockers increased by approximately 10% and prescriptions for alpha-blockers increased by approximately 15%, with no significant differences between the two groups.Cardiovascular Events and Death
At the end of the study, 105 patients had had a first cardiovascular event, 58 in group 1 and 47 in group 2 (the distribution in each group is shown in the table in the Supplementary Appendix). There was no significant difference in the likelihood of a first cardiovascular event (primary end point) between group 1 and group 2 (hazard ratio, 0.78; 95% CI, 0.53 to 1.14; adjusted P=0.20) (Figure 3AFigure 3
Time to the Primary End Point of a First Cardiovascular Event before (Panel A) and after (Panel B) Censoring of Data on Patients at the Time of Initiation of Dialysis.). Censoring data on patients at the time of initiation of dialysis did not significantly affect the hazard ratio (1.04; 95% CI, 0.66 to 1.65) (Figure 3B). There were no significant differences between the two groups in the frequency and incidence of death from any cause (31 deaths [10%] in group 1 and 21 deaths [7%] in group 2; hazard ratio, 0.66; 95% CI, 0.38 to 1.15; adjusted P=0.14), incidence of death from cardiovascular causes (4% and 3%, respectively; hazard ratio, 0.74; 95% CI, 0.33 to 1.70; adjusted P=0.48), mean time to worsening of NYHA class (P=0.97), percentage of patients undergoing cardiovascular intervention (7% and 6%, respectively), incidence of hospital admission (61% and 59%, respectively), or mean duration of hospitalization for cardiovascular reasons (33.0 and 28.2 days, respectively).Findings on Echocardiography
Echocardiographic assessments were available for 451 patients at baseline. There were no significant least-square mean changes in left ventricular mass index between baseline (120.3±35.0 and 118.0±34.3 g per square meter in groups 1 and 2, respectively) and year 1 (a change of −4.6 and −3.3 g per square meter, respectively) and year 2 (a change of −6.4 and −7.8 g per square meter, respectively); the changes between groups at year 1 and year 2 also did not differ significantly (year 1, P=0.59; year 2, P=0.65).
Quality of Life
At year 1, the quality of life (measured with the use of the SF-36) was significantly better in group 1 than in group 2 with regard to general health (P=0.003), mental health (P<0.001), physical function (P<0.001), physical role (P=0.01), social function (P=0.006), and vitality (P<0.001) (Figure 4AFigure 4
Changes from Baseline to Year 1 in SF-36 Quality-of-Life Scores (Panel A) and Mean Changes in Estimated GFR (Panel B), and the Time to Dialysis (Panel C) during the Study.). At year 2, the significant difference between groups was maintained for general health (P=0.008) and vitality (P=0.01).Renal Function
At baseline, the mean estimated GFR was 24.9±6.3 ml per minute for group 1 and 24.2±6.0 ml per minute for group 2. At year 1, the mean estimated GFR had decreased by 3.6±6.7 ml per minute in group 1 and by 3.1±5.3 ml per minute in group 2 (P=0.40) (Figure 4B). At the end of the study, the mean estimated GFR was 18.1±11.5 ml per minute in group 1 and 19.2±19.0 ml per minute in group 2 (P=0.36). In total, 127 patients in group 1 and 111 patients in group 2 started dialysis (Figure 4C). On average, there was no significant difference between the two groups in the last available estimated GFR value before the initiation of dialysis (group 1, 10.9±3.4 ml per minute; group 2, 12.1±4.2 ml per minute). A difference in the time to initiation of dialysis became apparent at 18 months, after which the time to dialysis was shorter in group 1 than in group 2 (P=0.03). The decrease in estimated GFR over time did not differ significantly according to the length of time patients remained in the study (less than 1 year, 1 to 2 years, and more than 2 years) in either group (data not shown). Using the Modification of Diet in Renal Disease IV study equation to calculate the mean estimated GFR did not change the results significantly (at baseline, 20.2±6.6 ml per minute in group 1 and 20.4±7.1 ml per minute in group 2; at year 1, 17.6±10.0 and 17.8±8.1 ml per minute, respectively; and at year 2, 17.8±16.6 and 18.2±28.8 ml per minute, respectively; all comparisons were not significant).
Adverse Events
Adverse events, most of which were mild or moderate, occurred in 93% of patients in group 1 and 90% of patients in group 2 (Table 2). Overall, there were no major differences in adverse events between the two groups. There were more vascular disorders in group 1 (P<0.001), mainly because of a greater incidence of hypertension (P=0.005), and more headaches (P=0.03). Arteriovenous fistula thrombosis occurred in 12 of the 127 patients who underwent dialysis in group 1 and in 8 of the 111 patients who underwent dialysis in group 2 (130 and 108 patient-years spent receiving dialysis, respectively).
Discussion
Our findings indicate that as compared with partial correction, early and complete correction of anemia to hemoglobin levels between 13.0 and 15.0 g per deciliter has no beneficial effect on the time to a first cardiovascular event in patients with chronic kidney disease of stage 3 or 4 and mild-to-moderate anemia from renal causes. There were no significant differences between the two groups in the frequency of death from cardiovascular causes or the time to death from cardiovascular causes or any cause.
The lack of a beneficial effect of the normalization of hemoglobin levels on cardiovascular outcomes thus appears to be consistent and independent of whether patients have sufficient residual renal function or require dialysis.9-11 Although we found no evidence of adverse cardiovascular effects of the normalization of hemoglobin levels, the hazard ratios for the primary end point, death from any cause, and death from cardiovascular causes consistently (although not significantly) favored the group with the lower hemoglobin target range, which is similar to trends in previous studies.9,11 The imbalance favoring the lower target range disappeared when data on patients receiving dialysis were censored (Figure 3B).
Subgroup analysis indicated that there were fewer cardiovascular events in group 1 than in group 2 (34 vs. 39 events) before the initiation of dialysis. In contrast, among patients undergoing dialysis, those in group 1 had more cardiovascular events than those in group 2 (24 vs. 8 events). This difference might be related to the intermittent increase in hemoconcentration after dialysis.
Several large analyses have shown an inverse relation between hemoglobin levels and adverse outcomes and have also identified anemia as an independent risk factor for left ventricular growth and morbidity and mortality from cardiovascular causes.21,22 The lack of benefit from the normalization of hemoglobin levels in our study suggests that although the degree of anemia is a strong indicator of poor prognosis, complete correction of anemia does not improve outcomes. It also suggests that factors causing the anemia, not the anemia itself, have adverse consequences. Alternatively, with increasing hemoglobin values, possible adverse effects such as vascular events might come into play, counterbalancing the potential benefits.9,23 In this issue of the Journal, Singh et al.24 report an increased risk of complications and death from cardiovascular causes among patients with stage 3 or 4 chronic kidney disease in response to correction of anemia, with a target hemoglobin level of 13.5 g per deciliter, as compared with the standard target of 11.3 g per deciliter. However, among our patients with chronic kidney disease, we found no significant difference in the risk of cardiovascular outcomes between those who underwent partial and those who underwent complete correction of anemia. To explain the observed differences in risk between the study by Singh et al. and our study, potential differences in the study populations and design should be considered. Moreover, in the study by Singh et al., the low end of the target hemoglobin range for complete correction of anemia was lower than that in our study, and the initial and final doses of epoetin were more than twice those used in our study to achieve similar hemoglobin levels, indicating a more severe profile of cardiovascular risk, with an annual event rate nearly thrice that in our study. Singh et al. censored data on patients after they started renal replacement therapy. In our study, when the analysis was limited to patients with chronic kidney disease who did not need renal replacement therapy, there was no difference at all between the two groups in the time to the first cardiovascular event (Figure 3B).
A major limitation of our study was that the rate of cardiovascular events was considerably lower than anticipated: 6% per year, as compared with 15% per year in the study by Levin et al.21 At the end of the study, only half the predicted number of cardiovascular events (105 actual events vs. 200 expected) had occurred, and almost half the patients were receiving dialysis. However, the lack of benefit from complete hemoglobin correction appears to be driven not by the lower-than-expected number of events but by the lack of an effect. A possible explanation for the lower overall incidence of cardiovascular events is that the nephrologists progressively increased their awareness of and protection against the heavy burden of cardiovascular disease, together with the usually better prognosis of patients enrolled in randomized controlled trials than of patients not enrolled. For example, nearly 70% of patients at the beginning of the trial were receiving agents that block the renin–angiotensin system, and approximately 40% were receiving beta-blockers (Table 1).
Renal end points were secondary, and we did not comprehensively assess renal function (such as by directly measuring GFR rather than estimating GFR, or measuring proteinuria). Moreover, there were no firm criteria in the protocol for the initiation of dialysis. Although the two groups did not differ significantly in the mean decrease in estimated GFR (despite an absolute difference of approximately 0.5 ml per minute per year), the observed difference in the time to dialysis was significant (P=0.03). However, given the lack of standardized rules for the initiation of analysis, these data should be interpreted with caution. As for cardiovascular outcomes, observational studies have recently reported an inverse relation between the hemoglobin level and the decrease in GFR in patients with renal disease.25-27 Previous, smaller interventional trials found either no effect of high target ranges of hemoglobin levels on the decrease in GFR15,28-30 or even an attenuation.31 Experimental evidence suggests that epoetin may exert renoprotective effects independent of its erythropoietic capacity.32,33
In line with previous studies,11,34,35 our study showed significant benefits of higher hemoglobin targets on the quality of life. These benefits were particularly evident with regard to physical function, vitality, and mental health, which generally deteriorate as chronic kidney disease progresses.36 The capacity for physical exercise also diminishes progressively, and anemia has been shown to be a clinically significant cause of this decline.37
In conclusion, we found that in patients with chronic kidney disease of stage 3 or 4 and mild-to-moderate anemia, the normalization of hemoglobin levels to 13.0 to 15.0 g per deciliter did not reduce cardiovascular events as compared with the use of a lower target range (10.5 to 11.5 g per deciliter). Thus, the CREATE study adds direct evidence to confirm the current best practice guidelines, which recommend partial correction of anemia and not routine normalization of hemoglobin levels.7,38
Supported by F. Hoffmann–La Roche.
Dr. Drüeke reports receiving consulting fees and lecture fees from F. Hoffmann–La Roche and consulting fees, lecture fees, and grant support from Amgen and Genzyme; Dr. Locatelli, consulting fees, lecture fees, and grant support from F. Hoffmann–La Roche, Amgen, Dompé, and Shire; Dr. Clyne, consulting fees and lecture fees from F. Hoffmann–LaRoche; Dr. Eckardt, consulting fees, lecture fees, and grant support from F. Hoffmann–La Roche and Ortho Biotech, consulting fees and lecture fees from Amgen, and consulting fees from Affymax; Dr. Macdougall, consulting fees, lecture fees, and grant support from Amgen, Ortho Biotech, Roche, and Affymax; Dr. Tsakiris, lecture fees from Amgen; and Drs. Burger and Scherhag, being employees of F. Hoffmann–La Roche. No other potential conflict of interest relevant to this article was reported.
We thank the late Professor Dr. Fernando Valderrábano for his invaluable contribution as a member of the CREATE steering committee; Drs. Caesar Escrig and Chris Dougherty for their close involvement in the early phase of the study; Dr. Juliana Wild and Ms. Judith Gysin for reviewing the patient data from the case-report forms; Mr. Viktor Nendel, Ms. Maritza Melendez, and Ms. Susan Gries for their assistance with statistical analyses; Dr. Martin Bexon and Dr. Juliana Wild for assistance in drafting the manuscript; Ms. Regine Schrumpf for her operational leadership of the study; Ms. Rachel Hosie for the data management; and all the clinical monitors of the study, without whose continuous commitment to the collection of high-quality data this study would not have been possible.
Source Information
From Inserm Unité 507 and Assistance Publique–Hôpitaux de Paris, Necker Hospital, Division of Nephrology, Paris (T.B.D.); the Department of Nephrology and Dialysis, Ospedale A. Manzoni, Lecco, Italy (F.L.); the Department of Nephrology, University Hospital Lund, Lund, Sweden (N.C.); the Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany, and the First Medical Clinic, Mannheim University Hospital, University of Heidelberg, Heidelberg, Germany (K.-U.E.); the Department of Renal Medicine, King's College Hospital, London (I.C.M.); the Department of Nephrology, General Hospital of Veria, Veria, Greece (D.T.); and the Pharmaceutical Division, F. Hoffmann–La Roche, Basel, Switzerland (H.-U.B., A.S.).
Address reprint requests to Dr. Drüeke at Unité 507 de l'INSERM and Service de Néphrologie, Hôpital Necker, Université Paris-V, Paris, France, or at drueke@necker.fr.
The committee members and investigators in the Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) trial are listed in the Appendix.
Appendix
The following committee members and investigators participated in the CREATE study (the numbers of enrolled patients are given in parentheses): Steering Committee — Necker Hospital, Paris — T.B. Drüeke (chair); Ospedale A. Manzoni, Lecco, Italy — F. Locatelli (vice chair); Södertälje Hospital, Södertälje, Sweden — N. Clyne; University of Erlangen–Nürnberg, Erlangen, Germany — K.-U. Eckardt; King's College Hospital, London — I.C. Macdougall; General Hospital of Veria, Veria, Greece — D. Tsakiris; End Point Committee — University of Rotterdam, Thoraxcenter, Rotterdam, the Netherlands — J. Roelandt; Klinik im Park, Zurich, Switzerland — W. Kiowski; Necker Hospital, Paris — P. Jungers; Data and Safety Monitoring Board — University of Minnesota, Minneapolis — R.N. Foley (chair); University Hospital Basel, Switzerland — M. Pfisterer; University of British Columbia, St. Paul's Hospital, Vancouver, Canada — A. Levin; Nottingham Clinical Research Group, Nottingham, United Kingdom — A. Skene; Investigators — Austria — Landeskrankenhaus St. Poelten (3) — P. Balcke; Allgemeines Öffentliches Krankenhaus, Linz (3) — G. Biesenbach; Belgium — Hôpital Erasme, Brussels (5) — C. Tielemans; Universitair Ziekenhuis Antwerp, Edegem (5) — G. Verpooten; Academisch Ziekenhuis Vrije Universiteit Brussel, Brussels (3) — J. Sennesael; China — Queen Mary Hospital, Hong Kong (10) — T. Chan; Czech Republic — Faculty Hospital, Ostrava (18) — I. Valkovsky; Fakultativn Nemocnice, Brno (13) — M. Hertlova; Hospital Havirov, Havirov (3) — S. Schwarzova; Faculty Hospital, Olomouc (1) — Z. Kosatikova; Denmark — Herlev Amtssygehus, Herlev (10) — S. Strandgaard; Roskilde Amtssygehuset, Roskilde (9) — K. Rasmussen; Fredericia Sygehus, Fredericia (8) — G. Steffensen; Holbaek Centralsygehus, Holbaek (1) — K. Soelling; Finland — Keski-Suomen Keskussairaala, Jyväskylä (16) — A. Koistinen; Tampere University Hospital, Tampere (4) — J. Mustonen; France — Centre Hospitalier La Beauchée, Saint Brieuc (13) — P. Simon; Centre Hospitalier de Boulogne, Boulogne (10) — P. Bataille; Groupe Hospitalier Sud, Amiens (8) — G. Choukroun; Centre Hospitalier, Angoulême (8) — L. Yver; Centre Hospitalier Universitaire–Hôpital Lapeyronie, Montpellier (7) — B. Canaud; Centre Hospitalier Louis Pasteur, Colmar (6) — B. Faller; Centre Hospitalier Universitaire–Hôpital Pellegrin, Bordeaux (5) — C. Combe; Hôpital Necker, Paris (5) — J.-P. Grunfeld; Hôpital Edouard Herriot, Lyon (5) — M. Laville; Centre Hospitalier Universitaire–Hôpitaux de Brabois, Vandoeuvre-lès-Nancy (4) — M. Kessler; Centre Hospitalier, Troyes (2) — F. Schillinger; Germany — Charité, Virchow Klinikum, Berlin (6) — U. Frei, K.-U. Eckardt; Nephrologisches Zentrum, Villingen-Schwenningen (5) — G. Schultze; Internistisch/Nephrologische Praxis, Homburg (2) — R. Bambauer; Facharztpraxis für Innere Medizin, Würzburg (2) — L. Schramm; Greece — Laiko General Hospital, Athens (6) — C. Stathakis; General Hospital of Veria, Veria (5) — D. Tsakiris; Hippokratio Hospital, Thessaloniki (4) — D. Memmos; Ireland — Beaumont Hospital, Dublin (1) — P. Conlon; Italy — Ospedale Alessandro Manzoni, Lecco (20) — F. Locatelli, L. del Vecchio; Fondazione S. Maugeri, Pavia (8) — G. Villa; Ospedale S. Eugenio, Rome (7) — C. Meloni; Ospedale di Parma, Parma (6) — S. David; Policlinico S. Orsola–Malpighi, Bologna (6) — S. Stefoni; Azienda Ospedale Università di Padova, Padua (4) — S. Cantaro; Azienda Ospedaliera D., Naples (4) — C. De Pascale; Ospedale Civile Bassini, Cinisello Balsamo (3) — G. Buccianti; Ospedale Civile di Sondrio, Sondrio (3) — V. De Cristofaro; Ospedale di Cattinara, Trieste (3) — G. Panzetta; Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo (3) — C. Stallone; Ospedale G. Brotzu, Cagliari (2) — P. Altieri; Ospedale di Circolo, Busto Arsizio (2) — A. Giangrande; Ospedale Civile di Vimercate, Vimercate (1) — A. Sessa; Ospedale S. Camillo, Rome (1) — S. Di Giulio; Mexico — Unidad De Investigación Clinica Nefrologia, Cuernavaca (12) — T. Bochicchio; Centro De Investigación Del Noroeste, S.C., Tijuana (9) — J. Barbosa; Norway — Ullevael Sykehus, Oslo (7) — H. Gudmundsdottir; Poland — Collegium Medicum, Krakow (25) — W. Sulowicz; Akademia Medyczna Im. Piastow Slaskich, Wroclaw (17) — M. Klinger; Klinika Nefrologii, Gdansk (13) — B. Rutkowski; Wojewodzki Szpital, Kielce (9) — K. Bidas; Portugal — Hospital Santa Cruz, Carnaxide (4) — M. Pais; Hospital Sao Jao, Porto (3) — M. Pestana; Hospital Garcia de Horta, Almada (3) — P. Ponces; Hospital Sams, Lisbon (1) — A. Nogueira; Russian Federation — St. Petersburg State Medical Academy after Mechnikov Dialysis, St. Petersburg (5) — A. Zemtchenkov; Russian Medical Academy of Postgraduate Education, Moscow (4) — V. Ermolenko; Central Republican Clinical Hospital #2, Moscow (4) — N. Khasabov; Research Institute of Transplantology and Artificial Organs, Moscow (4) — N. Tomilina; St. Petersburg State Medical Academy, St. Petersburg (1) — M. Komandenko; Spain — Hospital De La Paz, Madrid (12) — J. De Miguel Alonso; Hospital General Universitario, Madrid (9) — J. Luno Fernandez; Hospital General Valle de Hebron, Barcelona (8) — L. Piera; Hospital Universitario La Fe, Nephrology, Valencia (4) — J.-M. Cruz; Hospital General de Gran, Las Palmas de Gran Canaria (2) — L. Palop; Sweden — Karolinska Hospital, Stockholm (7) — M. Soederhaell; Örebro Medical Center, Örebro (6) — M. Tidman; Laenssjukhuset Ryhov, Jönköping (5) — C. Frisenette-Fich; Central Hospital, Karlstad (5) — L. Weiss; Sundsvall Hospital, Sundsvall (4) — E. Olausson; Sas Boras Hospital, Boras (3) — F. Nielsen; Taiwan — National Cheng Kung University Hospital, Tainan (20) — J.-J. Huang; National Taiwan University Hospital, Taipei (13) — K.-D. Wu; Veterans General Hospital, Taichung (11) — K.-H. Shu; Chang Gung Memorial Hospital, Taoyuan (6) — C.-C. Yu; Thailand — Siriraj Hospital, Mahidol, Bangkok (8) — K. Vareesangthip; Maharaj Nakorn Chiang Mai Hospital, Chiang Mai (4) — D. Lumlertgul; Turkey — Ankara University of Medicine, Ankara (10) — G. Nergisoglu; Ege University of Medicine, Izmir (10) — M. Ozkahya; Hacettepe University of Medicine, Ankara (2) — M. Arici; Istanbul University of Cerrahpasa Medicine Faculty, Istanbul (1) — E. Erek; United Kingdom — King's College Hospital, London (15) — I.C. Macdougall; Belfast City Hospital, Belfast (12) — P. Maxwell; Royal Southampton Hospital, Southampton (9) — M. Rogerson; St. Helier Hospital, Carshalton (4) — P. Andrews; Freeman Hospital, Newcastle upon Tyne (3) — R. Wilkinson; Charing Cross Hospital, London (1) — E. Brown; Hope Hospital, Salford (1) — G. Wood.
- References
References
1
Weiner DE ,Tighiouart H ,Vlagopoulos PT , et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005;16:1803-1810
CrossRef | Web of Science | Medline2
Ma JZ ,Ebben J ,Xia H ,Collins AJ . Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-619
Web of Science | Medline3
Madore F ,Lowrie EG ,Brugnara C , et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 1997;8:1921-1929
Web of Science | Medline4
Mocks J . Cardiovascular mortality in haemodialysis patients treated with epoetin beta -- a retrospective study. Nephron 2000;86:455-462
CrossRef | Medline5
Ofsthun N ,Labrecque J ,Lacson E ,Keen M ,Lazarus JM . The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003;63:1908-1914
CrossRef | Web of Science | Medline6
Collins AJ . Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003;18:Suppl 2:ii2-ii6
Medline7
Locatelli F ,Aljama P ,Barany P , et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19:Suppl 2:ii1-ii47
CrossRef | Medline8
Pisoni RL ,Bragg-Gresham JL ,Young EW , et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94-111
CrossRef | Web of Science | Medline9
Besarab A ,Bolton WK ,Browne JK , et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590
Full Text | Web of Science | Medline10
Foley RN ,Parfrey PS ,Morgan J , et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-1335
CrossRef | Web of Science | Medline11
Parfrey PS ,Foley RN ,Wittreich BH ,Sullivan DJ ,Zagari MJ ,Frei D . Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005;16:2180-2189
CrossRef | Web of Science | Medline12
Portoles J ,Torralbo A ,Martin P ,Rodrigo J ,Herrero JA ,Barrientos A . Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997;29:541-548
CrossRef | Web of Science | Medline13
Hayashi T ,Suzuki A ,Shoji T , et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35:250-256
CrossRef | Web of Science | Medline14
Valderrabano F . Improvement and prevention of left ventricular hypertrophy in predialysis patients. J Am Soc Nephrol 2000;11:78A-78A15
Roger SD ,McMahon LP ,Clarkson A , et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004;15:148-156
CrossRef | Web of Science | Medline16
Levin A ,Djurdjev O ,Thompson C , et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005;46:799-811
CrossRef | Web of Science | Medline17
Macdougall IC . CREATE: new strategies for early anaemia management in renal insufficiency. Nephrol Dial Transplant 2003;18:Suppl 2:ii13-ii16
Medline18
Ware JE Jr ,Sherbourne CD . The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483
CrossRef | Web of Science | Medline19
Schiller NB ,Shah PM ,Crawford M , et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989;2:358-367
Medline20
Kisslo J . Recommendations for continuous quality improvement in echocardiography. J Am Soc Echocardiogr 1995;8:S1-S28
CrossRef | Medline21
Levin A ,Thompson CR ,Ethier J , et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-134
CrossRef | Web of Science | Medline22
Foley RN ,Parfrey PS ,Harnett JD ,Kent GM ,Murray DC ,Barre PE . The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61
CrossRef | Web of Science | Medline23
Regidor DL ,Kopple JD ,Kovesdy CP , et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-1191
CrossRef | Web of Science | Medline24
Singh AK ,Szczech L ,Tang KL , et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098
Full Text | Web of Science | Medline25
Cusick M ,Chew EY ,Hoogwerf B , et al. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study report no. 26. Kidney Int 2004;66:1173-1179
CrossRef | Web of Science | Medline26
Mohanram A ,Zhang Z ,Shahinfar S ,Keane WF ,Brenner BM ,Toto RD . Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004;66:1131-1138
CrossRef | Web of Science | Medline27
Rossing K ,Christensen PK ,Hovind P ,Tarnow L ,Rossing P ,Parving HH . Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004;66:1596-1605
CrossRef | Web of Science | Medline28
Rossert J ,Levin A ,Roger SD , et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006;47:738-729
CrossRef | Web of Science | Medline29
Roth D ,Smith RD ,Schulman G , et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994;24:777-784
Web of Science | Medline30
Furuland H ,Linde T ,Ahlmen J ,Christensson A ,Strombom U ,Danielson BG . A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18:353-361
CrossRef | Web of Science | Medline31
Gouva C ,Nikolopoulos P ,Ioannidis JP ,Siamopoulos KC . Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753-760
CrossRef | Web of Science | Medline32
Sharples EJ ,Patel N ,Brown P , et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004;15:2115-2124
CrossRef | Web of Science | Medline33
Rossert J ,Eckardt KU . Erythropoietin receptors: their role beyond erythropoiesis. Nephrol Dial Transplant 2005;20:1025-1028
CrossRef | Web of Science | Medline34
Revicki DA ,Brown RE ,Feeny DH , et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548-554
CrossRef | Web of Science | Medline35
McMahon LP ,Mason K ,Skinner SL ,Burge CM ,Grigg LE ,Becker GJ . Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000;15:1425-1430
CrossRef | Web of Science | Medline36
Klang B ,Clyne N . Well-being and functional ability in uraemic patients before and after having started dialysis treatment. Scand J Caring Sci 1997;11:159-166
Web of Science | Medline37
Clyne N ,Jogestrand T ,Lins LE ,Pehrsson SK . Progressive decline in renal function induces a gradual decrease in total hemoglobin and exercise capacity. Nephron 1994;67:322-326
CrossRef | Medline38
National Kidney Foundation
CrossRef | Medline
- Citing Articles (484)
Citing Articles
1
SUNIL BHANDARI. (2012) Iron therapy in patients with chronic kidney disease. Transfusion Alternatives in Transfusion Medicineno-no
CrossRef2
R. Minutolo, G. Conte, B. Cianciaruso, V. Bellizzi, A. Camocardi, L. De Paola, L. De Nicola. (2012) Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Nephrology Dialysis Transplantation
CrossRef3
Paola Cassis, Lorenzo Gallon, Ariela Benigni, Marilena Mister, Anna Pezzotta, Samantha Solini, Elena Gagliardini, Daniela Cugini, Mauro Abbate, Sistiana Aiello, Federica Rocchetta, Pierangela Scudeletti, Norberto Perico, Marina Noris, Giuseppe Remuzzi. (2012) Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney International
CrossRef4
Wolfgang C. Winkelmayer, Daniel E. Weiner. (2012) Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Trends Through April 2011’: No Surprises Yet. American Journal of Kidney Diseases 59:2, 312-314
CrossRef5
Ronald Pyram, Abhishek Kansara, Mary Ann Banerji, Lisel Loney-Hutchinson. (2012) Chronic kidney disease and diabetes. Maturitas 71:2, 94-103
CrossRef6
Bhanu P. Nalla, John Freedman, Gregory M.T. Hare, C. David Mazer. (2012) Update on Blood Conservation for Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia 26:1, 117-133
CrossRef7
Mana Yahiro, Takahiro Kuragano, Aritoshi Kida, Rie Kitamura, Minoru Furuta, Yukiko Hasuike, Yoshinaga Otaki, Hiroshi Nonoguchi, Takeshi Nakanishi. (2012) The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients. Clinical and Experimental Nephrology
CrossRef8
H. Reichel. (2012) Klinisch relevante Faktoren der Progressionshemmung. Der Nephrologe
CrossRef9
Nahla A. Al-Ageel, Sinaa A. Al-Aqeel, Norah O. Abanmy, Jamal S. Alwakeel, Alaa Sabry, Khalid A. Alsaran. (2012) Appropriateness of anemia management in hemodialysis patients. Saudi Pharmaceutical Journal 20:1, 85-91
CrossRef10
Jolanta Malyszko, Maciej Drozdz, Agnieszka Zolkiewicz, Boleslaw Rutkowski. (2012) Renal Anemia Treatment with ESA in Hemodialysis Patients in Relation to Early versus Late Referral in Everyday Clinical Practice in Central and Eastern European Countries: Baseline Data. Kidney and Blood Pressure Research 35:1, 58-67
CrossRef11
Charles J. Diskin. (2012) Towards Erythropoietin Equations That Estimate Oxygen Delivery rather than Static Hemoglobin Targets. Nephron Clinical Practice 120:1, c48-c53
CrossRef12
M. Cooke, A. Lamplugh, S. Naudeer, M. Edey, S. Bhandari. (2012) Efficacy and Tolerability of Accelerated-Dose Low-Molecular-Weight Iron Dextran (Cosmofer) in Patients with Chronic Kidney Disease. American Journal of Nephrology 35:1, 69-74
CrossRef13
Jay B. Wish. 2012. Anemia in chronic kidney disease. , 142-147.
CrossRef14
Uyen Duong, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Joshua J. Zaritsky, Isaac Teitelbaum, Csaba P. Kovesdy, Rajnish Mehrotra. (2012) Mortality Associated with Dose Response of Erythropoiesis-Stimulating Agents in Hemodialysis versus Peritoneal Dialysis Patients. American Journal of Nephrology 35:2, 198-208
CrossRef15
Andrew S Levey, Josef Coresh. (2012) Chronic kidney disease. The Lancet 379:9811, 165-180
CrossRef16
K. L. Johansen, F. O. Finkelstein, D. A. Revicki, C. Evans, S. Wan, M. Gitlin, I. L. Agodoa. (2011) Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrology Dialysis Transplantation
CrossRef17
Huseyin Naci, Gregory de Lissovoy, Christopher Hollenbeak, Brian Custer, Axel Hofmann, William McClellan, Matthew Gitlin. (2011) Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis. Journal of Medical Economics1-12
CrossRef18
Ummuhani Ozel Turkcu, Guldeniz Karadeniz Cakmak, Ebru Ofluoglu Demir, Hakan Bakkal, Muzaffer Onder Oner, Rahsan Dilek Okyay, İbrahim Cumhur Bassorgun, Mehmet Akif Ciftcioglu. (2011) The Effect of Erythropoietin on Anastomotic Healing of Irradiated Rats. Journal of Investigative Surgery111207111156002
CrossRef19
J.-C. Galle, K. Claes, I. Kiss, C. G. Winearls, H. Herlitz, A. Guerin, S. Di Giulio, M. G. Suranyi, I. Bridges, J. Addison, M. Farouk. (2011) An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Nephrology Dialysis Transplantation
CrossRef20
Jacques B. Rottembourg, Aurélie Dansaert. (2011) Faisabilité de la stratégie d’administration de la darbepoetin alfa tous les 15 jours : expérience 2005–2007 d’un centre de dialyse. Néphrologie & Thérapeutique 7:7, 549-557
CrossRef21
Iain C. Macdougall. (2011) New Anemia Therapies: Translating Novel Strategies From Bench to Bedside. American Journal of Kidney Diseases
CrossRef22
Ruben Poesen, Bert Bammens, Kathleen Claes, Dirk Kuypers, Yves Vanrenterghem, Diethard Monbaliu, Pieter Evenepoel. (2011) Prevalence and determinants of anemia in the immediate postkidney transplant period. Transplant International 24:12, 1208-1215
CrossRef23
Hicham Skali, Scott D. Solomon. (2011) Reducing Infarct Size With EPO in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Kidney Diseases 58:6, 876-878
CrossRef24
Robert E. Schmidt, Dongyan Feng, Qiuling Wang, Karen G. Green, Lisa L. Snipes, Michael Yamin, Michael Brines. (2011) Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2Akita) diabetic mouse sympathetic ganglia. Experimental Neurology 232:2, 126-135
CrossRef25
B. Terrier, M. Resche-Rigon, E. Andres, F. Bonnet, E. Hachulla, I. Marie, E. Rosenthal, P. Cacoub, . (2011) Prevalence, characteristics and prognostic significance of anemia in daily practice. QJM
CrossRef26
D. Fliser, F. Dellanna, M. Koch, J. Seufert, O. Witzke, I.A. Hauser. (2011) The PRIMAVERA study protocol design: Evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease. Contemporary Clinical Trials 32:6, 786-792
CrossRef27
Vimal K Derebail, Patrick H Nachman, Nigel S Key, Heather Ansede, Ronald J Falk, Wayne D Rosamond, Abhijit V Kshirsagar. (2011) Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. Kidney International 80:9, 992-999
CrossRef28
Stefan Heidenreich, Frank Leistikow, Stefan Zinn, Jörg Baumann, Andreas Atzeni, Vitomir Bajeski, Jörn Dietzmann, Gert-Peter Dragoun. (2011) Monthly Administration of a Continuous Erythropoietin Receptor Activator Provides Efficient Haemoglobin Control in Non-Dialysis Patients during Routine Clinical Practice. Clinical Drug Investigation1
CrossRef29
Carsten Hafer, Thomas Becker, Jan T Kielstein, Elisabeth Bahlmann, Anke Schwarz, Nikolai Grinzoff, Daria Drzymala, Isabelle Bonnard, Nicolas Richter, Frank Lehner, Juergen Klempnauer, Hermann Haller, Jana Traeder, Danilo Fliser. (2011) High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation. Kidney International
CrossRef30
Tadao Akizawa, Fumitake Gejyo, Shinichi Nishi, Yasuhiko Iino, Yuzou Watanabe, Masashi Suzuki, Akira Saito, Takashi Akiba, Hideki Hirakata, Shunichi Fukuhara, Satoshi Morita, Michiaki Hiroe, Yoshiyuki Hada, Makoto Suzuki, Makoto Akaishi, Manabu Iwasaki, Yoshiharu Tsubakihara, . (2011) Positive Outcomes of High Hemoglobin Target in Patients With Chronic Kidney Disease Not on Dialysis: A Randomized Controlled Study. Therapeutic Apheresis and Dialysis 15:5, 431-440
CrossRef31
Meredith A. Atkinson, Susan L. Furth. (2011) Anemia in children with chronic kidney disease. Nature Reviews Nephrology 7:11, 635-641
CrossRef32
David C. Mendelssohn, Phil McFarlane. (2011) Conditionally Funded Field Evaluations-A Solution to the Economic Barriers Limiting Evidence Generation in Dialysis?. Seminars in Dialysis 24:5, 556-559
CrossRef33
Ajay K. Singh. (2011) ESA treatment in dialysis patients: Where do we go now?. Dialysis & Transplantation 40:9, 387-389
CrossRef34
Marshall M. Joffe, Wei Peter Yang, Harold Feldman. (2011) G-Estimation and Artificial Censoring: Problems, Challenges, and Applications. Biometricsno-no
CrossRef35
Cecilia A. Cotton, Patrick J. Heagerty. (2011) A Data Augmentation Method for Estimating the Causal Effect of Adherence to Treatment Regimens Targeting Control of an Intermediate Measure. Statistics in Biosciences 3:1, 28-44
CrossRef36
Katerina Pavenski, Gregory M. T. Hare, C. David Mazer. (2011) Erythropoietic neuroprotection: Holy Grail or potential to fail?. Intensive Care Medicine 37:9, 1403-1405
CrossRef37
Gianni Biolo, Gianfranco Guarnieri, Rocco Barazzoni, Giovanni Panzetta. (2011) Complete correction of anemia by erythropoiesis-stimulating agents is associated with insulin resistance in hemodialysis patients. Clinical and Experimental Medicine 11:3, 181-187
CrossRef38
Holger Schmid, Helmut Schiffl, Stephan R. Lederer. (2011) Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient. Current Opinion in Nephrology and Hypertension 20:5, 465-470
CrossRef39
Oluwatoyin F Bamgbola. (2011) Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney International 80:5, 464-474
CrossRef40
Yi Zhang, Mae Thamer, James S Kaufman, Dennis J Cotter, Miguel A Hernán. (2011) High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney International 80:6, 663-669
CrossRef41
Patrick S. Parfrey. (2011) Erythropoietin-stimulating Agents in Chronic Kidney Disease: A Response to Hyporesponsiveness. Seminars in Dialysis 24:5, 495-497
CrossRef42
Ana Lurdes Agostinho Cabrita, Ana Pinho, Anabela Malho, Elsa Morgado, Marília Faísca, Hermínio Carrasqueira, Ana Paula Silva, Pedro Leão Neves. (2011) Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. International Urology and Nephrology 43:3, 835-840
CrossRef43
Ajay K Singh. (2011) Is there a deleterious effect of erythropoietin in end-stage renal disease?. Kidney International 80:6, 569-571
CrossRef44
Inger Karin Lægreid, Knut Aasarød, Marit Jordhøy. (2011) End-stage renal disease and recruitment to randomized trials: Why is it so difficult? Results from a survey among Norwegian nephrologists. Scandinavian Journal of Urology and Nephrology 45:4, 285-289
CrossRef45
Arman Altincatal, Robert B. MacArthur, Sergio Teruya, Stephen Helmke, Mathew S. Maurer. (2011) A Dosing Algorithm for Erythropoietin Alpha in Older Adults with Heart Failure and a Preserved Ejection Fraction. Cardiovascular Therapeuticsno-no
CrossRef46
Stephen L Seliger, Amy D Zhang, Matthew R Weir, Loreen Walker, Van Doren Hsu, Afshin Parsa, Clarissa J Diamantidis, Jeffrey C Fink. (2011) Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney International 80:3, 288-294
CrossRef47
Amy Barton Pai, Todd Conner, Charles R. McQuade, Jonathan Olp, Paul Hicks. (2011) Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. BioMetals 24:4, 603-613
CrossRef48
Erik Lipšic, Peter van der Meer, Dirk J. van Veldhuisen. (2011) Erythropoiesis-Stimulating Agents and Heart Failure. Cardiovascular Therapeutics 29:4, e52-e59
CrossRef49
Francisco Cano, Claudia Alarcon, Marta Azocar, Carolina Lizama, Ana Maria Lillo, Angela Delucchi, Mariluz Gonzalez, Patricia Arellano, Iris Delgado, Maria Teresa Droguett. (2011) Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatric Nephrology 26:8, 1303-1310
CrossRef50
Brigitte Schiller, Anatole Besarab. (2011) Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care. Current Medical Research and Opinion 27:8, 1539-1550
CrossRef51
Peter Buren, Ruben L. Velez, Nosratola D. Vaziri, Xin J. Zhou. (2011) Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. International Urology and Nephrology
CrossRef52
Xianfang Rong, Xiaofen Mo, Tiantian Ren, Sixing Yang, Weien Yuan, Jingyan Dong, Yan Wang, Xin Wang. (2011) Neuroprotective effect of erythropoietin-loaded composite microspheres on retinal ganglion cells in rats. European Journal of Pharmaceutical Sciences 43:4, 334-342
CrossRef53
F. Locatelli, L. Del Vecchio. (2011) Erythropoietic response to erythropoiesis-stimulating agents and outcome: should we give up the haemoglobin target approach?. Nephrology Dialysis Transplantation 26:7, 2069-2071
CrossRef54
Emmanuel Villar, Michel Lièvre, Michèle Kessler, Vincent Lemaître, Eric Alamartine, Michel Rodier, Maud François, Philippe Zaoui, Olivier Moranne, Gabriel Choukroun, Abdallah Guerraoui, Anne Jolivot, Gérard Janin, Bernard Branger, Anne-Elisabeth Heng, Catherine Boudray, Alvine Bissery, Muriel Rabilloud, Claire Pouteil-Noble. (2011) Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial. Journal of Diabetes and its Complications 25:4, 237-243
CrossRef55
Iain C. Macdougall. (2011) Anaemia and chronic renal failure. Medicine 39:7, 425-428
CrossRef56
Judit Gordon, Jeffrey B. Kopp. (2011) Off the Beaten Renin–Angiotensin–Aldosterone System Pathway: New Perspectives on Antiproteinuric Therapy. Advances in Chronic Kidney Disease 18:4, 300-311
CrossRef57
J. Grau-Amorós, F. Formiga, A. Urrutia. (2011) Anemia en la insuficiencia cardiaca crónica. Revista Clínica Española 211:7, 354-359
CrossRef58
Gaurav Gupta, Michael J. Choi. (2011) Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies?. Seminars in Dialysis 24:4, 379-381
CrossRef59
Patrick Mark, Alan Jardine. (2011) Cardiovascular complications of chronic renal disease. Medicine 39:7, 421-424
CrossRef60
Adeera Levin, Paul E. Stevens. (2011) Early detection of CKD: the benefits, limitations and effects on prognosis. Nature Reviews Nephrology 7:8, 446-457
CrossRef61
Angela Yee-Moon WANG. (2011) Cardiovascular risk in diabetic end-stage renal disease patients. Journal of Diabetes 3:2, 119-131
CrossRef62
D. W. Coyne. (2011) The future of intravenous iron in nephrology. NDT Plus 4:Supplement 1, i6-i9
CrossRef63
Kitty J Jager, Bengt Lindholm, David Goldsmith, Danilo Fliser, Andrzej Wiecek, Gultekin Suleymanlar, Alberto Ortiz, Ziad Massy, Alberto Martinez-Castelao, Rajiv Agarwal, Peter J Blankestijn, Adrian Covic, Gerard London, Carmine Zoccali, Friedo W Dekker. (2011) Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?. Kidney International Supplements 1:1, 21-23
CrossRef64
Ellen Campbell, Paul Kalra. (2011) CARDIORENAL MEDICINE: PARTNERS IN PRACTICE?. Journal of Renal Care 37:2, 68-71
CrossRef65
Andrej Bren, Miha Arnol, Aljoša Kandus, Janez Varl, Manca Oblak, Jelka Lindič, Jernej Pajek, Bojan Knap, Damjan Kovač, Gregor Mlinšek, Jadranka Buturović-Ponikvar. (2011) Treatment of Anemia With Epoetin in Kidney Transplant Recipients. Therapeutic Apheresis and Dialysis 15:3, 257-260
CrossRef66
M. Z. Molnar, M. E. Czira, A. Rudas, A. Ujszaszi, B. Haromszeki, J. P. Kosa, P. Lakatos, G. Beko, E. Sarvary, M. Varga, K. Fornadi, M. Novak, L. Rosivall, I. Kiss, A. Remport, D. J. Goldsmith, C. P. Kovesdy, I. Mucsi. (2011) Association between the malnutrition-inflammation score and post-transplant anaemia. Nephrology Dialysis Transplantation 26:6, 2000-2006
CrossRef67
A. A. Butt, T. Umbleja, J. W. Andersen, R. T. Chung, K. E. Sherman, . (2011) The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Alimentary Pharmacology & Therapeutics 33:11, 1234-1244
CrossRef68
P. A. Kalra. (2011) Introducing iron isomaltoside 1000 (Monofer(R))--development rationale and clinical experience. NDT Plus 4:Supplement 1, i10-i13
CrossRef69
Lawrence J. Schneiderman. (2011) Defining Medical Futility and Improving Medical Care. Journal of Bioethical Inquiry 8:2, 123-131
CrossRef70
Michèle Kessler, Paul Landais, Pierre Bataille, Laurent Yver, Sébastien Koné, Sandrine Kraemer, Georges Brillet, Éric Canivet. (2011) Prise en charge de l’anémie des patients hémodialysés en France : résultats de l’étude DiaNE à trois ans (DiaNE 2). Néphrologie & Thérapeutique 7:3, 182-187
CrossRef71
Dirk J. van Veldhuisen, Stefan D. Anker, Piotr Ponikowski, Iain C. Macdougall. (2011) Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nature Reviews Cardiology 8:9, 485-493
CrossRef72
Ingar Holme, Are H Aastveit, Niklas Hammar, Ingmar Jungner, Göran Walldius. (2011) High blood hemoglobin concentration as risk factor of major atherosclerotic cardiovascular events in 114,159 healthy men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Annals of Medicine1-11
CrossRef73
V. Wizemann. (2011) Epoetin bubble: a severe German case Honi soit qui mal y pense. Nephrology Dialysis Transplantation 26:5, 1750-1752
CrossRef74
D. Regidor, W. M. McClellan, R. Kewalramani, A. Sharma, B. D. Bradbury. (2011) Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. Nephrology Dialysis Transplantation 26:5, 1583-1591
CrossRef75
M. W. Bergmann, S. Haufe, F. von Knobelsdorff-Brenkenhoff, H. Mehling, R. Wassmuth, I. Munch, A. Busjahn, J. Schulz-Menger, J. Jordan, F. C. Luft, R. Dietz. (2011) A pilot study of chronic, low-dose epoetin- following percutaneous coronary intervention suggests safety, feasibility, and efficacy in patients with symptomatic ischaemic heart failure. European Journal of Heart Failure 13:5, 560-568
CrossRef76
Robert J. Mentz, Eldrin F. Lewis. (2011) Epidemiology of Cardiorenal Syndrome. Cardiology Clinics 29:2, 301-314
CrossRef77
James S. Kaufman. (2011) Relationship of Erythropoiesis-Stimulating Agent Dose and Responsiveness and Adverse Outcomes in CKD. American Journal of Kidney Diseases 57:5, 661-663
CrossRef78
Noémie Jourde-Chiche, Laetitia Dou, Claire Cerini, Françoise Dignat-George, Philippe Brunet. (2011) Vascular Incompetence in Dialysis Patients-Protein-Bound Uremic Toxins and Endothelial Dysfunction. Seminars in Dialysis 24:3, 327-337
CrossRef79
Eugene Muchnik, Joshua Kaplan. (2011) HIF prolyl hydroxylase inhibitors for anemia. Expert Opinion on Investigational Drugs 20:5, 645-656
CrossRef80
Hirotaka Komaba, Masafumi Fukagawa. (2011) Dialysis: Is the road to survival paved with good mineral management?. Nature Reviews Nephrology 7:4, 185-186
CrossRef81
Jeffrey S Warren, Ying Zhao, Raymond Yung, Anjali Desai. (2011) Recombinant Human Erythropoietin Suppresses Endothelial Cell Apoptosis and Reduces the Ratio of Bax to Bcl-2 Proteins in the Aortas of Apolipoprotein E–Deficient Mice. Journal of Cardiovascular Pharmacology 57:4, 424-433
CrossRef82
A. Hertig, F. Ferrer-Marin. (2011) Correction of anaemia on dialysis: did we forget physiology?. Nephrology Dialysis Transplantation 26:4, 1120-1122
CrossRef83
, Tadao Akizawa, Hirofumi Makino, Seiichi Matsuo, Tsuyoshi Watanabe, Enyu Imai, Kosaku Nitta, Yasuo Ohashi, Akira Hishida. (2011) Management of anemia in chronic kidney disease patients: baseline findings from Chronic Kidney Disease Japan Cohort Study. Clinical and Experimental Nephrology 15:2, 248-257
CrossRef84
Serkan SAYGI, Gulay ASCI, Hamad DHEIR, Soner DUMAN, Meral KAYIKCIOGLU, Mumtaz YILMAZ, Mehmet OZKAHYA, Ercan OK. (2011) Ventricular arrhythmia in dialysis patients: A link with higher hemoglobin levels?. Hemodialysis International 15:2, 250-255
CrossRef85
Kosaku Nitta. (2011) Pathogenesis and therapeutic implications of cardiorenal syndrome. Clinical and Experimental Nephrology 15:2, 187-194
CrossRef86
E. Neven, T. M. De Schutter, G. J. Behets, A. Gupta, P. C. D'Haese. (2011) Iron and vascular calcification. Is there a link?. Nephrology Dialysis Transplantation 26:4, 1137-1145
CrossRef87
Alberto Palazzuoli, Ilaria Quatrini, Anna Calabrò, Giovanni Antonelli, Maria Caputo, Maria S. Campagna, Beatrice Franci, Ranuccio Nuti. (2011) Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. Clinical and Experimental Medicine 11:1, 43-48
CrossRef88
Gültekin Süleymanlar, Kamil Serdengeçti, Mehmet R. Altiparmak, Kitty Jager, Nurhan Seyahi, Ekrem Erek. (2011) Trends in Renal Replacement Therapy in Turkey, 1996-2008. American Journal of Kidney Diseases 57:3, 456-465
CrossRef89
Patrick S Parfrey. (2011) Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure. Current Opinion in Nephrology and Hypertension 20:2, 177-181
CrossRef90
Jay B. Wish. (2011) Hemoglobin Variability as a Predictor of Mortality: What's a Practitioner to Do?. American Journal of Kidney Diseases 57:2, 190-193
CrossRef91
SUNIL V BADVE, CARMEL M HAWLEY, DAVID W JOHNSON. (2011) Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD?. Nephrology 16:2, 144-153
CrossRef92
Brian E. Michel. (2011) The association of red blood cell parameters with mortality in a population of hemodialysis patients. Dialysis & Transplantation 40:2, 72-77
CrossRef93
Enrico Vizzardi, Tania Bordonali, Elena Tanghetti, Marco Metra, Livio Dei Cas. (2011) Anaemia and heart failure. Central European Journal of Medicine 6:1, 11-25
CrossRef94
Takeshi Hasegawa, Jennifer L Bragg-Gresham, Ronald L Pisoni, Bruce M Robinson, Shunichi Fukuhara, Takashi Akiba, Akira Saito, Kiyoshi Kurokawa, Tadao Akizawa. (2011) Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney International 79:3, 340-346
CrossRef95
Lev Osherovich. (2011) EPO plays defense. Science-Business eXchange 4:2,
CrossRef96
Geoffrey Teehan, Robert L. Benz. (2011) An Update on the Controversies in Anemia Management in Chronic Kidney Disease: Lessons Learned and Lost. Anemia 2011, 1-5
CrossRef97
Eric D. Weinhandl, David T. Gilbertson, Allan J. Collins. (2011) Association of Mean Weekly Epoetin Alfa Dose with Mortality Risk in a Retrospective Cohort Study of Medicare Hemodialysis Patients. American Journal of Nephrology 34:4, 298-308
CrossRef98
Vittoria Mastromarino, Massimo Volpe, Maria B. Musumeci, Camillo Autore, Elena Conti. (2011) Erythropoietin and the heart: facts and perspectives. Clinical Science 120:2, 51-63
CrossRef99
Young-Il Cho, Daniel J Cho. (2011) Hemorheology and Microvascular Disorders. Korean Circulation Journal 41:6, 287
CrossRef100
Irfan Khan, Mahesh Krishnan, Anupam Kothawala, Akhtar Ashfaq. (2011) Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis. BMC Nephrology 12:1, 22
CrossRef101
L. T. Goodnough, A. Maniatis, P. Earnshaw, G. Benoni, P. Beris, E. Bisbe, D. A. Fergusson, H. Gombotz, O. Habler, T. G. Monk, Y. Ozier, R. Slappendel, M. Szpalski. (2011) Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. British Journal of Anaesthesia 106:1, 13-22
CrossRef102
Andrew A. House, Mikko Haapio, Johan Lassus, Rinaldo Bellomo, Claudio Ronco. (2011) Pharmacological Management of Cardiorenal Syndromes. International Journal of Nephrology 2011, 1-8
CrossRef103
Ashraf Mikhail, Rajesh Shrivastava, Donald Richardson. (2011) Renal Association Clinical Practice Guideline on Anaemia of Chronic Kidney Disease. Nephron Clinical Practice 118:s1, c101-c124
CrossRef104
Csaba P. Kovesdy. (2011) How KDIGO Will (or Will Not) Influence the Management of Hyperphosphatemia. Seminars in Dialysis 24:1, 35-36
CrossRef105
Miklos Zsolt Molnar, Istvan Mucsi, Iain C. Macdougall, James E. Marsh, Magdi Yaqoob, John Main, Aisling E. Courtney, Damien Fogarty, Ashraf Mikhail, Gabriel Choukroun, Colin D. Short, Adrian Covic, David J. Goldsmith. (2011) Prevalence and Management of Anaemia in Renal Transplant Recipients: Data from Ten European Centres. Nephron Clinical Practice 117:2, c127-c134
CrossRef106
D. Goldsmith. (2011) Extraordinary popular delusions and the madness of crowds: puncturing the epoetin bubble--lessons for the future. Nephrology Dialysis Transplantation 26:1, 24-28
CrossRef107
Julie Gilg, Lynsey Webb, Terry Feest, Damian Fogarty. (2011) Chapter 9: Haemoglobin, Ferritin and Erythropoietin amongst UK Adult Dialysis Patients in 2009: National and Centre-Specific Analyses. Nephron Clinical Practice 119:s2, c149-c177
CrossRef108
(2011) Nihon Toseki Igakkai Zasshi 44:5, 375-382
CrossRef109
Kazuhiko Tsuruya. (2011) Nihon Toseki Igakkai Zasshi 44:12, 1139-1142
CrossRef110
Danilo Fliser. 2011. Tissue Protection and Regeneration Aided by Erythropoietin and Erythropoietin-derived Peptides. , 93-101.
CrossRef111
Ana Antic, Zoran Stanojkovic. (2011) Red blood cells transfusions in oncological patients treated with radio- and chemoterapy. Vojnosanitetski pregled 68:1, 28-34
CrossRef112
D. Choi, S. A. Schroer, S. Y. Lu, L. Wang, X. Wu, Y. Liu, Y. Zhang, H. Y. Gaisano, K.-U. Wagner, H. Wu, R. Retnakaran, M. Woo. (2010) Erythropoietin protects against diabetes through direct effects on pancreatic cells. Journal of Experimental Medicine 207:13, 2831-2842
CrossRef113
Luís Gustavo Modelli Andrade, Juliana Maria Gera Abrão, Maria Fernanda Cordeiro Carvalho. (2010) Anemia at one year is an independent risk factor of graft survival. International Urology and Nephrology
CrossRef114
Kosmas I. Paraskevas, Ioannis Kotsikoris, Sotirios A. Koupidis, Alexandros A. Tzovaras, Dimitri P. Mikhailidis. (2010) Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention. International Urology and Nephrology 42:4, 999-1006
CrossRef115
A. L. M. de Francisco. (2010) Individualizing anaemia therapy. NDT Plus 3:6, 519-526
CrossRef116
Fiona M. Clement, Scott Klarenbach, Marcello Tonelli, Natasha Wiebe, Brenda Hemmelgarn, Braden J. Manns. (2010) An Economic Evaluation of Erythropoiesis-Stimulating Agents in CKD. American Journal of Kidney Diseases 56:6, 1050-1061
CrossRef117
Kristine S Schonder, Shelby L Corman, Whitney (Yu-Hui) Hung. (2010) Early Risk Factors for Persistent Anemia After Kidney Transplantation. Pharmacotherapy 30:12, 1214-1220
CrossRef118
J. H. Lau, A. S. Gangji, C. G. Rabbat, K. S. Brimble. (2010) Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. Nephrology Dialysis Transplantation 25:12, 4002-4009
CrossRef119
Francis Verbeke, Wim Van Biesen, Raymond Vanholder, Luc Van Bortel. (2010) Noninvasive evaluation of large artery function and structure in dialysis patients: Clinical applications. Artery Research 4:4, 138-143
CrossRef120
Hiroyuki Ito, Yuichiro Takeuchi, Hidenori Ishida, Aya Otawa, Akane Shibayama, Shinichi Antoku, Mariko Abe, Mizuo Mifune, Michiko Togane. (2010) Mild anemia is frequent and associated with micro- and macroangiopathies in patients with type 2 diabetes mellitus. Journal of Diabetes Investigation 1:6, 273-278
CrossRef121
Eileen O’Meara, Simon Denus. (2010) Management of Anemia and Iron Deficiency in Heart Failure. Current Treatment Options in Cardiovascular Medicine 12:6, 532-548
CrossRef122
Himmelfarb, Jonathan, Ikizler, T. Alp, . (2010) Hemodialysis. New England Journal of Medicine 363:19, 1833-1845
Full Text123
A. Kainz, B. Mayer, R. Kramar, R. Oberbauer. (2010) Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrology Dialysis Transplantation 25:11, 3701-3706
CrossRef124
P. Stenvinkel. (2010) Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. Journal of Internal Medicine 268:5, 456-467
CrossRef125
Atsushi Ogino, Genzou Takemura, Masanori Kawasaki, Akiko Tsujimoto, Hiromitsu Kanamori, Longhu Li, Kazuko Goto, Rumi Maruyama, Itta Kawamura, Toshiaki Takeyama, Tomonori Kawaguchi, Takatomo Watanabe, Yoshiyuki Moriguchi, Hideki Saito, Takako Fujiwara, Hisayoshi Fujiwara, Shinya Minatoguchi. (2010) Erythropoietin Receptor Signaling Mitigates Renal Dysfunction-Associated Heart Failure by Mechanisms Unrelated to Relief of Anemia. Journal of the American College of Cardiology 56:23, 1949-1958
CrossRef126
Imari Mimura, Masaomi Nangaku. (2010) The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nature Reviews Nephrology 6:11, 667-678
CrossRef127
Jeffrey S Berns. (2010) Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?. Current Opinion in Nephrology and Hypertension 19:6, 567-572
CrossRef128
Francesco Locatelli, Kai-Uwe Eckardt, Iain C. Macdougall, Dimitrios Tsakiris, Naomi Clyne, Hans-Ulrich Burger, Armin Scherhag, Tilman B. Drüeke. (2010) Value of N -terminal brain natriuretic peptide as a prognostic marker in patients with CKD: results from the CREATE study. Current Medical Research and Opinion 26:11, 2543-2552
CrossRef129
H. Sorg, J.W. Kuhbier, B. Menger, K. Reimers, Y. Harder, P.M. Vogt. (2010) Die Rolle von Erythropoietin bei der Verbesserung der Wundheilung. Der Chirurg 81:11, 993-998
CrossRef130
Jaya Gobin, Aura Cernii, Rosella McLean, Fredric O. Finkelstein, David B. Simon. (2010) Conversion from Epoetin Alfa to Darbepoetin Alfa for Management of Anaemia in a Community Chronic Kidney Disease Centre. Clinical Drug Investigation1
CrossRef131
Lucia Del Vecchio, Francesco Locatelli. 2010. Erythropoietin and Iron Therapy in Patients with Renal Failure. , 357-367.
CrossRef132
Neil Soni, Benjamin Thomas. 2010. The Benefits of Allogeneic Erythrocyte Transfusion: What Evidence Do We Have?. , 68-81.
CrossRef133
Antonis S. Manolis, Spyridon Koulouris, Kostas Triantafyllou, Dimitris Sakellariou, Sokratis Pastromas, Helen Melita. 2010. Anemia and Cardiovascular Disease. , 229-251.
CrossRef134
Wolfgang Jelkmann. (2010) Biosimilar epoetins and other “follow-on” biologics: Update on the European experiences. American Journal of Hematology 85:10, 771-780
CrossRef135
Kai-Uwe Eckardt. (2010) Chronic kidney disease: Are elevated doses of ESAs associated with adverse outcomes?. Nature Reviews Nephrology 6:10, 566-568
CrossRef136
Enyu Imai, Ryohei Yamamoto, Hiromichi Suzuki, Tsuyoshi Watanabe. (2010) Incidence of symptomatic stroke and cancer in chronic kidney disease patients treated with epoetins. Clinical and Experimental Nephrology 14:5, 445-452
CrossRef137
Andrew A. House, Mikko Haapio, Johan Lassus, Rinaldo Bellomo, Claudio Ronco. (2010) Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes. American Journal of Kidney Diseases 56:4, 759-773
CrossRef138
Bernard CANAUD, Annie RODRIGUEZ, Leila CHENINE, Marion MORENA, Isabelle JAUSSENT, Hélène LERAY-MORAGUES, Annie PICARD, Jean-Paul CRISTOL. (2010) Whole-blood viscosity increases significantly in small arteries and capillaries in hemodiafiltration. Does acute hemorheological change trigger cardiovascular risk events in hemodialysis patient?. Hemodialysis International 14:4, 433-440
CrossRef139
Solomon, Scott D., Uno, Hajime, Lewis, Eldrin F., Eckardt, Kai-Uwe, Lin, Julie, Burdmann, Emmanuel A., de Zeeuw, Dick, Ivanovich, Peter, Levey, Andrew S., Parfrey, Patrick, Remuzzi, Giuseppe, Singh, Ajay K., Toto, Robert, Huang, Fannie, Rossert, Jerome, McMurray, John J.V., Pfeffer, Marc A., . (2010) Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine 363:12, 1146-1155
Full Text140
Wolfgang C. Winkelmayer. (2010) Confusion about the Appropriate Use of Erythropoiesis-Stimulating Agents in Patients Undergoing Maintenance Dialysis. Seminars in Dialysis 23:5, 486-491
CrossRef141
Agustín Urrutia, Emilio Sacanella, Jordi Mascaro, Francesc Formiga. (2010) Anemia en el anciano. Revista Española de Geriatría y Gerontología 45:5, 291-297
CrossRef142
Ajay K Singh. (2010) What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?. Current Opinion in Nephrology and Hypertension 19:5, 420-424
CrossRef143
J. Fort, X. Cuevas, F. Garcia, R. Perez-Garcia, F. Llados, J. Lozano, A. Martin-Malo, . (2010) Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study. Nephrology Dialysis Transplantation 25:8, 2702-2710
CrossRef144
Ajay K. Singh. (2010) Diabetes, Anemia and CKD: Why TREAT?. Current Diabetes Reports 10:4, 291-296
CrossRef145
Patrick R. Lawler, Kristian B. Filion, Mark J. Eisenberg. (2010) Correcting Anemia in Heart Failure: The Efficacy and Safety of Erythropoiesis-Stimulating Agents. Journal of Cardiac Failure 16:8, 649-658
CrossRef146
G. Sturm, C. Lamina, E. Zitt, K. Lhotta, F. Lins, O. Freistatter, U. Neyer, F. Kronenberg. (2010) Sex-specific association of time-varying haemoglobin values with mortality in incident dialysis patients. Nephrology Dialysis Transplantation 25:8, 2715-2722
CrossRef147
W. R. Ho, M. J. Germain, J. Garb, S. Picard, M.-K. Mackie, C. Bartlett, E. J. Will. (2010) Use of 12x/month haemoglobin monitoring with a computer algorithm reduces haemoglobin variability. Nephrology Dialysis Transplantation 25:8, 2710-2714
CrossRef148
Morrell M Avram. (2010) Symposium proceedings. Kidney International 78, S1-S2
CrossRef149
Steven Fishbane, Allen R Nissenson. (2010) Anemia management in chronic kidney disease. Kidney International 78, S3-S9
CrossRef150
Rory McQuillan, Sarbjit V. Jassal. (2010) Neuropsychiatric complications of chronic kidney disease. Nature Reviews Nephrology 6:8, 471-479
CrossRef151
Dena E. Rifkin, Wolfgang C. Winkelmayer. (2010) Medication Issues in Older Individuals With CKD. Advances in Chronic Kidney Disease 17:4, 320-328
CrossRef152
T. Hamid, S. D. Prabhu. (2010) Erythropoietin and ventricular remodelling: a VEGF-dependent neovascularity. Cardiovascular Research 87:1, 6-7
CrossRef153
D. Kiski, H. Reinecke. (2010) Herz und Niere. Der Internist 51:7, 850-856
CrossRef154
L. A. Szczech, D. B. Bregman, R. A. Harrington, D. Morris, A. Butcher, T. A. Koch, L. T. Goodnough, M. Wolf, J. E. Onken. (2010) Randomized Evaluation of efficacy and safety of ferric carboxymaltose in Patients with iron deficiency Anaemia and Impaired Renal function (REPAIR-IDA): rationale and study design. Nephrology Dialysis Transplantation 25:7, 2368-2375
CrossRef155
Melissa Chamney, Karen Pugh-Clarke, Theodora Kafkia, Iain Wittwer. (2010) CE: Continuing Education Article
MANAGEMENT OF ANAEMIA IN CHRONIC KIDNEY DISEASE. Journal of Renal Care 36:2, 102-111
CrossRef156
Adeera Levin, Monica Carol Beaulieu. (2010) TREAT: Implications for Guideline Updates and Clinical Care. American Journal of Kidney Diseases 55:6, 984-987
CrossRef157
Guido Filler, Shih-Han Susan Huang, Ajay P. Sharma. (2010) Racial Disparities in Hemoglobin Concentration in Children With CKD. American Journal of Kidney Diseases 55:6, 981-983
CrossRef158
D. Goldsmith, A. Covic. (2010) Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA). Nephrology Dialysis Transplantation 25:6, 1734-1737
CrossRef159
Satoru Kuriyama. (2010) The target hemoglobin in non-dialysis CKD: still a matter for debate?. Clinical and Experimental Nephrology 14:3, 298-299
CrossRef160
Yoshiharu Tsubakihara, Shinichi Nishi, Takashi Akiba, Hideki Hirakata, Kunitoshi Iseki, Minoru Kubota, Satoru Kuriyama, Yasuhiro Komatsu, Masashi Suzuki, Shigeru Nakai, Motoshi Hattori, Tetsuya Babazono, Makoto Hiramatsu, Hiroyasu Yamamoto, Masami Bessho, Tadao Akizawa. (2010) 2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. Therapeutic Apheresis and Dialysis 14:3, 240-275
CrossRef161
Giacomo Zoppini, Giovanni Targher, Michel Chonchol, Carlo Negri, Vincenzo Stoico, Isabella Pichiri, Giuseppe Lippi, Michele Muggeo, Enzo Bonora. (2010) Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. Atherosclerosis 210:2, 575-580
CrossRef162
Andrzej Wiecek. (2010) Anemia: To TREAT or not to TREAT—that is the question. Nature Reviews Nephrology 6:5, 254-255
CrossRef163
Norbert Maurin. (2010) Die Rolle der Thrombozyten bei Atherosklerose, Diabetes mellitus und chronischer Niereninsuffizienz. Medizinische Klinik 105:5, 339-344
CrossRef164
Irene M. Van Der Meer, Piero Ruggenenti, Giuseppe Remuzzi. (2010) THE DIABETIC CKD PATIENT-A MAJOR CARDIOVASCULAR CHALLENGE. Journal of Renal Care 36, 34-46
CrossRef165
William T. Abraham, Inder S. Anand, Marc Klapholz, Piotr Ponikowski, Debra Scarlata, Scott M. Wasserman, Dirk J. Van Veldhuisen. (2010) Treatment of Anemia With Darbepoetin Alfa in Heart Failure. Congestive Heart Failure 16:3, 87-95
CrossRef166
Rose S. Cohen, Paula Karlin, Madeline Yushak, Donna Mancini, Mathew S. Maurer. (2010) The Effect of Erythropoietin on Exercise Capacity, Left Ventricular Remodeling, Pressure-Volume Relationships, and Quality of Life in Older Patients With Anemia and Heart Failure With Preserved Ejection Fraction. Congestive Heart Failure 16:3, 96-103
CrossRef167
Neha M Patel, Orlando M Gutiérrez, Dennis L Andress, Daniel W Coyne, Adeera Levin, Myles Wolf. (2010) Vitamin D deficiency and anemia in early chronic kidney disease. Kidney International 77:8, 715-720
CrossRef168
Christi Hayes, Anis Alam, Julie Black-Peart, Samy I. McFarlane. (2010) Mitigating the Cardiovascular Risk of Anemia in Patients with Type 2 Diabetes and CKD: Does Darbepoetin Help? The TREAT Trial. Current Diabetes Reports 10:2, 87-89
CrossRef169
Seul-Ki Jeong, Young I. Cho, Marc Duey, Robert S. Rosenson. (2010) Cardiovascular Risks of Anemia Correction with Erythrocyte Stimulating Agents: Should Blood Viscosity Be Monitored for Risk Assessment?. Cardiovascular Drugs and Therapy 24:2, 151-160
CrossRef170
Amy Staples, Craig Wong. (2010) Risk factors for progression of chronic kidney disease. Current Opinion in Pediatrics 22:2, 161-169
CrossRef171
N. D. Taylor, J. C. Way, P. A. Silver, P. Cironi. (2010) Anti-glycophorin single-chain Fv fusion to low-affinity mutant erythropoietin improves red blood cell-lineage specificity. Protein Engineering Design and Selection 23:4, 251-260
CrossRef172
Eugenie Pedagogos. (2010) Coronary artery, cerebrovascular and peripheral vascular disease. Nephrology 15, S19-S23
CrossRef173
Albert Lam, Siddharth Shah, James Paparello. (2010) Outpatient Management of Chronic Kidney Disease: Proteinuria, Anemia and Bone Disease as Therapeutic Targets. Disease-a-Month 56:4, 215-232
CrossRef174
Ranjani N. Moorthi, Sharon M. Moe, Tilman Drüeke, Katrin Uhlig. (2010) All Research Does Not a Guideline Make!. American Journal of Kidney Diseases 55:4, 631-634
CrossRef175
LUCIA DEL VECCHIO, FRANCESCO LOCATELLI. (2010) Erythropoietin and iron therapy in patients with renal failure. Transfusion Alternatives in Transfusion Medicine 11:1, 20-29
CrossRef176
Thomas D Stamos, Marc A Silver. (2010) Management of anemia in heart failure. Current Opinion in Cardiology 25:2, 148-154
CrossRef177
Ritu K Soni, Steven D Weisbord, Mark L Unruh. (2010) Health-related quality of life outcomes in chronic kidney disease. Current Opinion in Nephrology and Hypertension 19:2, 153-159
CrossRef178
Shravanthi R. Gandra, Fredric O. Finkelstein, Antonia V. Bennett, Eldrin F. Lewis, Tracy Brazg, Mona L. Martin. (2010) Impact of Erythropoiesis-Stimulating Agents on Energy and Physical Function in Nondialysis CKD Patients With Anemia: A Systematic Review. American Journal of Kidney Diseases 55:3, 519-534
CrossRef179
Jan Galle. (2010) Das kardiorenale Syndrom. Medizinische Klinik 105:3, 142-149
CrossRef180
Radica Z. Alicic, Katherine R. Tuttle. (2010) Management of the Diabetic Patient with Advanced Chronic Kidney Disease. Seminars in Dialysis 23:2, 140-147
CrossRef181
Kirsten L. Johansen, Fredric O. Finkelstein, Dennis A. Revicki, Matthew Gitlin, Christopher Evans, Tracy J. Mayne. (2010) Systematic Review and Meta-analysis of Exercise Tolerance and Physical Functioning in Dialysis Patients Treated With Erythropoiesis-Stimulating Agents. American Journal of Kidney Diseases 55:3, 535-548
CrossRef182
Lynda Szczech. (2010) Anemia trials: lessons for clinicians, politicians, and third-party payers. Kidney International 77:6, 479-480
CrossRef183
Patrick S. Parfrey, Tyler Wish. (2010) Quality of Life in CKD Patients Treated With Erythropoiesis-Stimulating Agents. American Journal of Kidney Diseases 55:3, 423-425
CrossRef184
Holger Schmid, Helmut Schiffl, Stephan R Lederer. (2010) Pharmacotherapy of end-stage renal disease. Expert Opinion on Pharmacotherapy 11:4, 597-613
CrossRef185
Iñigo Les, Eduardo Doval, Montserrat Flavià, Carlos Jacas, Guillermo Cárdenas, Rafael Esteban, Jaime Guardia, Juan Córdoba. (2010) Quality of life in cirrhosis is related to potentially treatable factors. European Journal of Gastroenterology & Hepatology 22:2, 221-227
CrossRef186
Steven Fishbane, Nobuyuki Miyawaki. (2010) Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure. Kidney International 77:3, 175-177
CrossRef187
Hideki Hirakata, Yoshiharu Tsubakihara, Fumitake Gejyo, Shinichi Nishi, Yasuhiko Iino, Yuzou Watanabe, Masashi Suzuki, Akira Saito, Takashi Akiba, Daijo Inaguma, Shunichi Fukuhara, Satoshi Morita, Michiaki Hiroe, Yoshiyuki Hada, Makoto Suzuki, Makoto Akaishi, Kazutaka Aonuma, Tadao Akizawa. (2010) Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients. Clinical and Experimental Nephrology 14:1, 28-35
CrossRef188
Ari B. Geller, Maria V. DeVita, Jehona Marku-Podvorica, Jordan L. Rosenstock, Georgia Panagopoulos, Michael F. Michelis. (2010) Increase in post-dialysis hemoglobin can be out of proportion and unrelated to ultrafiltration. Dialysis & Transplantation 39:2, 57-62
CrossRef189
Jocelyn Wiggins, Sanjeevkumar Patel. (2010) Management of chronic kidney disease in older adults. Aging Health 6:1, 41-51
CrossRef190
Katherine Ngo, Dipak Kotecha, Julia AE Walters, Luis Manzano, Alberto Palazzuoli, Dirk J van Veldhuisen, Marcus Flather, Katherine Ngo. 2010. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. .
CrossRef191
Abboud, Hanna, Henrich, William L., . (2010) Stage IV Chronic Kidney Disease. New England Journal of Medicine 362:1, 56-65
Full Text192
Gbemisola A. Adeseun, Jeffrey S. Berns. (2010) Erythropoietin Bundling: Innovative Remuneration or the Dawn of EPO-Profiling?. Seminars in Dialysis 23:1, 88-90
CrossRef193
Christina E. Lankhorst, Jay B. Wish. (2010) Anemia in renal disease: Diagnosis and management. Blood Reviews 24:1, 39-47
CrossRef194
Richard J. Payne, Chi-Huey Wong. (2010) Advances in chemical ligation strategies for the synthesis of glycopeptides and glycoproteins. Chemical Communications 46:1, 21
CrossRef195
J. B. Wetmore, S. K. Rigler, J. D. Mahnken, P. Mukhopadhyay, T. I. Shireman. (2010) Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage?. Nephrology Dialysis Transplantation 25:1, 198-205
CrossRef196
Viktorija Kuzema, Aivars Pētersons, Harijs Čerņevskis, Aivars Lejnieks. (2010) Renal anaemia: the role of haemoglobin control in patients with chronic kidney disease. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 64:3, 137-143
CrossRef197
David M. Spiegel, Irfan Khan, Mahesh Krishnan, Tracy J. Mayne. (2010) Changes in Hemoglobin Level Distribution in US Dialysis Patients From June 2006 to November 2008. American Journal of Kidney Diseases 55:1, 113-120
CrossRef198
M. Ketteler, P.H. Biggar. (2010) Kardiorenales Syndrom. Der Nephrologe 5:1, 49-57
CrossRef199
Norimasa Taniguchi, Takeshi Nakamura, Takahisa Sawada, Kinya Matsubara, Keizo Furukawa, Mitsuyoshi Hadase, Yoshifumi Nakahara, Takashi Nakamura, Hiroaki Matsubara. (2010) Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After ST-Elevated Acute Myocardial Infarction (EPOC-AMI). Circulation Journal 74:11, 2365-2371
CrossRef200
T. J. Littlewood. (2009) IS NORMALISING HAEMOGLOBIN IN PATIENTS WITH CKD HARMFUL AND IF SO, WHY?. Journal of Renal Care 35, 25-28
CrossRef201
(2009) Evidence-based Practice Guideline for the Treatment of CKD. Clinical and Experimental Nephrology 13:6, 537-566
CrossRef202
Rafael Ramirez, Julia Carracedo, Sonia Nogueras, Paula Buendia, Ana Merino, Sagrario Cañadillas, Mariano Rodríguez, Ciro Tetta, Alejandro Martin-Malo, Pedro Aljama. (2009) Carbamylated darbepoetin derivative prevents endothelial progenitor cell damage with no effect on angiogenesis. Journal of Molecular and Cellular Cardiology 47:6, 781-788
CrossRef203
Faramarz Tehrani, Pavittarpaul Dhesi, Daniel Daneshvar, Anita Phan, Asim Rafique, Robert J. Siegel, Bojan Cercek. (2009) Erythropoiesis Stimulating Agents in Heart Failure Patients with Anemia: A Meta-Analysis. Cardiovascular Drugs and Therapy 23:6, 511-518
CrossRef204
SATORU SANADA, HIROAKI TOYAMA, YUTAKA EJIMA, MITSUNOBU MATSUBARA. (2009) Potential for erythropoietin synthesis in kidney of uraemic rat alters depending on severity of renal failure. Nephrology 14:8, 735-742
CrossRef205
(2009) The D&T report. Dialysis & Transplantation 38:12, 484-487
CrossRef206
Kentaro Kohagura, Nozomi Tomiyama, Kozen Kinjo, Shuichi Takishita, Kunitoshi Iseki. (2009) Prevalence of anemia according to stage of chronic kidney disease in a large screening cohort of Japanese. Clinical and Experimental Nephrology 13:6, 614-620
CrossRef207
Robert N. Foley. (2009) Target hemoglobin trials in chronic kidney disease: design and interpretation issues. Pediatric Nephrology 24:12, 2279-2285
CrossRef208
Lisa K. Hicks, Matthew C. Cheung, Keyue Ding, Baktiar Hasan, Lesley Seymour, Aurélie Le Maître, Natasha B. Leighl, Frances A. Shepherd. (2009) Venous thromboembolism and nonsmall cell lung cancer. Cancer 115:23, 5516-5525
CrossRef209
Marsden, Philip A., . (2009) Treatment of Anemia in Chronic Kidney Disease — Strategies Based on Evidence. New England Journal of Medicine 361:21, 2089-2090
Full Text210
Pfeffer, Marc A., Burdmann, Emmanuel A., Chen, Chao-Yin, Cooper, Mark E., de Zeeuw, Dick, Eckardt, Kai-Uwe, Feyzi, Jan M., Ivanovich, Peter, Kewalramani, Reshma, Levey, Andrew S., Lewis, Eldrin F., McGill, Janet B., McMurray, John J.V., Parfrey, Patrick, Parving, Hans-Henrik, Remuzzi, Giuseppe, Singh, Ajay K., Solomon, Scott D., Toto, Robert, . (2009) A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. New England Journal of Medicine 361:21, 2019-2032
Full Text211
Macdougall, Iain C., Rossert, Jerome, Casadevall, Nicole, Stead, Richard B., Duliege, Anne-Marie, Froissart, Marc, Eckardt, Kai-Uwe, . (2009) A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia. New England Journal of Medicine 361:19, 1848-1855
Full Text212
M. Klapholz, W. T. Abraham, J. K. Ghali, P. Ponikowski, S. D. Anker, B. Knusel, Y. Sun, S. M. Wasserman, D. J. van Veldhuisen. (2009) The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. European Journal of Heart Failure 11:11, 1071-1077
CrossRef213
B. B. Newsome, S. J. Onufrak, D. G. Warnock, W. M. McClellan. (2009) Exploration of anaemia as a progression factor in African Americans with cardiovascular disease. Nephrology Dialysis Transplantation 24:11, 3404-3411
CrossRef214
T.S. Dharmarajan, David Widjaja. (2009) Erythropoiesis-Stimulating Agents in Anemia: Use and Misuse. Journal of the American Medical Directors Association 10:9, 607-616
CrossRef215
David C. Mendelssohn, Jay B. Wish. (2009) Dialysis Delivery in Canada and the United States: A View From the Trenches. American Journal of Kidney Diseases 54:5, 954-964
CrossRef216
Tamara Isakova, Orlando M Gutiérrez, Myles Wolf. (2009) A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney International 76:7, 705-716
CrossRef217
Sarina van der Zee, Usman Baber, Sammy Elmariah, Jonathan Winston, Valentin Fuster. (2009) Cardiovascular risk factors in patients with chronic kidney disease. Nature Reviews Cardiology 6:9, 580-589
CrossRef218
IOANNIS TSOUCHNIKAS, EVANGELIA DOUNOUSI, STAMATINA PAPAKONSTANTINOU, KYRIAKOS IOANNOU, APOSTOLOS KELESIDIS, NIKOLAOS KOTZADAMIS, KYRIAKI XANTHOPOULOU, DIMITRIOS TSAKIRIS. (2009) Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients. Nephrology 14:6, 560-564
CrossRef219
Brian D. Bradbury, M. Alan Brookhart, Wolfgang C. Winkelmayer, Cathy W. Critchlow, Ryan D. Kilpatrick, Marshall M. Joffe, Harold I. Feldman, John F. Acquavella, Ouhong Wang, Kenneth J. Rothman. (2009) Evolving Statistical Methods to Facilitate Evaluation of the Causal Association Between Erythropoiesis-Stimulating Agent Dose and Mortality in Nonexperimental Research: Strengths and Limitations. American Journal of Kidney Diseases 54:3, 554-560
CrossRef220
Manish S. Patel, Jeffrey L. Carson. (2009) Anemia in the Preoperative Patient. Medical Clinics of North America 93:5, 1095-1104
CrossRef221
David A. Goodkin. (2009) The Normal Hematocrit Cardiac Trial Revisited. Seminars in Dialysis 22:5, 495-502
CrossRef222
Karen S. Servilla, Ajay K. Singh, William C. Hunt, Antonia M. Harford, Dana Miskulin, Klemens B. Meyer, Edward J. Bedrick, Mark R. Rohrscheib, Antonios H. Tzamaloukas, H. Keith Johnson, Philip G. Zager. (2009) Anemia Management and Association of Race With Mortality and Hospitalization in a Large Not-for-Profit Dialysis Organization. American Journal of Kidney Diseases 54:3, 498-510
CrossRef223
Sarbjit Vanita Jassal. (2009) Clinical Presentation of Renal Failure in the Aged: Chronic Renal Failure. Clinics in Geriatric Medicine 25:3, 359-372
CrossRef224
Michelle W. Krause, Rasib Raja, Anil Agarwal, Marcia R. Silver, Debra Scarlata, Angela Sciarra, Reshma Kewalramani. (2009) Every-Other-Week Darbepoetin Alfa in the Correction and Maintenance of Haemoglobin Levels in Elderly Patients with Chronic Kidney Disease. Drugs & Aging 26:8, 665-675
CrossRef225
M. Andreucci, G. Fuiano, P. Presta, G. Lucisano, F. Leone, L. Fuiano, V. Bisesti, P. Esposito, D. Russo, B. Memoli, T. Faga, A. Michael. (2009) Downregulation of cell survival signalling pathways and increased cell damage in hydrogen peroxide-treated human renal proximal tubular cells by alpha-erythropoietin. Cell Proliferation 42:4, 554-561
CrossRef226
J. J.V. McMurray, I. S. Anand, R. Diaz, A. P. Maggioni, C. O'Connor, M. A. Pfeffer, K. R. Polu, S. D. Solomon, Y. Sun, K. Swedberg, M. Tendera, D. J. van Veldhuisen, S. M. Wasserman, J. B. Young, . (2009) Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. European Journal of Heart Failure 11:8, 795-801
CrossRef227
K. Smith, D. Semple, S. Bhandari, A.-M. L. Seymour. (2009) Cellular basis of uraemic cardiomyopathy: a role for erythropoietin?. European Journal of Heart Failure 11:8, 732-738
CrossRef228
Steven Fishbane, David J Cohen, Daniel W Coyne, Arjang Djamali, Ajay K Singh, Jay B Wish. (2009) Posttransplant anemia: the role of sirolimus. Kidney International 76:4, 376-382
CrossRef229
Marc A. Pfeffer, Emmanuel A. Burdmann, Chao-Yin Chen, Mark E. Cooper, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Reshma Kewalramani, Andrew S. Levey, Eldrin F. Lewis, Janet McGill, John J.V. McMurray, Patrick Parfrey, Hans-Henrik Parving, Giuseppe Remuzzi, Ajay K. Singh, Scott D. Solomon, Robert Toto, Hajime Uno. (2009) Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases 54:1, 59-69
CrossRef230
Eswari Vilayur, David C. H. Harris. (2009) Emerging therapies for chronic kidney disease: what is their role?. Nature Reviews Nephrology 5:7, 375-383
CrossRef231
R. Vanholder, D. Abramowicz, J. B. Cannata-Andia, V. Cocchi, P. Cochat, A. Covic, K.-U. Eckardt, D. Fouque, O. Heimburger, S. Jenkins, A. MacLeod, E. Lindley, F. Locatelli, G. London, A. Marti i Monros, G. Spasovski, J. Tattersall, W. Van Biesen, C. Wanner, A. Wiecek, C. Zoccali. (2009) The future of European Nephrology 'Guidelines'--a declaration of intent by European Renal Best Practice (ERBP). NDT Plus 2:3, 213-221
CrossRef232
Fadi G. Hage, Rajesh Venkataraman, Gilbert J. Zoghbi, Gilbert J. Perry, Angelo M. DeMattos, Ami E. Iskandrian. (2009) The Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology 53:23, 2129-2140
CrossRef233
CSABA P KOVESDY, KAMYAR KALANTAR-ZADEH. (2009) Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease. Nephrology 14:4, 408-415
CrossRef234
Mahmut I Yilmaz, Alper Sonmez, Mutlu Saglam, Mahir Gulec, Selim Kilic, Tayfun Eyileten, Kayser Caglar, Yusuf Oguz, Abdulgaffar Vural, Mujdat Yenicesu, Carmine Zoccali. (2009) Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease. Kidney International 75:12, 1316-1321
CrossRef235
DENISE V O'SHAUGHNESSY, GRAHAME J ELDER. (2009) Review article: Patient-level outcomes: the missing link. Nephrology 14:4, 443-451
CrossRef236
S. D. Anker, A. Voors, D. Okonko, A. L. Clark, M. K. James, S. von Haehling, J. Kjekshus, P. Ponikowski, K. Dickstein, . (2009) Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. European Heart Journal 30:11, 1331-1339
CrossRef237
K. Chan, J. Moran, M. Hlatky, R. Lafayette. (2009) Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrology Dialysis Transplantation 24:6, 1956-1962
CrossRef238
P. Ferrari, J. Xiao, A. Ukich, A. Irish. (2009) Estimation of glomerular filtration rate: does haemoglobin discriminate between ageing and true CKD?. Nephrology Dialysis Transplantation 24:6, 1828-1833
CrossRef239
Nosratola D. Vaziri. (2009) Thrombocytosis in EPO-Treated Dialysis Patients May Be Mediated by EPO Rather Than Iron Deficiency. American Journal of Kidney Diseases 53:5, 733-736
CrossRef240
Christopher T. Chan. (2009) Cardiovascular Effects of Home Intensive Hemodialysis. Advances in Chronic Kidney Disease 16:3, 173-178
CrossRef241
Kamyar Kalantar-Zadeh, Grace H. Lee, Jessica E. Miller, Elani Streja, Jennie Jing, John A. Robertson, Csaba P. Kovesdy. (2009) Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients. American Journal of Kidney Diseases 53:5, 823-834
CrossRef242
Yves Vanrenterghem. (2009) Anemia After Kidney Transplantation. Transplantation 87:9, 1265-1267
CrossRef243
T. J. Arneson, D. Zaun, Y. Peng, C. A. Solid, S. Dunning, D. T. Gilbertson. (2009) Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population. Nephrology Dialysis Transplantation 24:5, 1378-1383
CrossRef244
Lars Pape, Thurid Ahlenstiel, Martin Kreuzer, Jens Drube, Kerstin Froede, Doris Franke, Jochen H. H. Ehrich, Marion Haubitz. (2009) Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome—a randomized prospective pilot trial. Pediatric Nephrology 24:5, 1061-1064
CrossRef245
A. Cases, E. Coll, S. Collado. (2009) Anemia en la insuficiencia renal crónica y sus implicaciones cardiovasculares. Medicina Clínica 132, 38-42
CrossRef246
Stefan A.J. Timmer, Karin De Boer, Paul Knaapen, Marco J.W. Götte, A.C. Van Rossum. (2009) The Potential Role of Erythropoietin in Chronic Heart Failure: From the Correction of Anemia to Improved Perfusion and Reduced Apoptosis?. Journal of Cardiac Failure 15:4, 353-361
CrossRef247
Diana Rucker, Marcello Tonelli. (2009) Cardiovascular risk and management in chronic kidney disease. Nature Reviews Nephrology 5:5, 287-296
CrossRef248
David M. Spiegel. (2009) Hemoglobin Variability in Chronic Kidney Disease: A Cross-Sectional Study. The American Journal of the Medical Sciences 337:5, 340-343
CrossRef249
Dhruv K. Singh, Peter Winocour, Ken Farrington. (2009) Erythropoietic stress and anemia in diabetes mellitus. Nature Reviews Endocrinology 5:4, 204-210
CrossRef250
Mathis Grossmann, Sianna Panagiotopolous, Ken Sharpe, Richard J. MacIsaac, Sophie Clarke, Jeffrey D. Zajac, George Jerums, Merlin C. Thomas. (2009) Low testosterone and anaemia in men with type 2 diabetes. Clinical Endocrinology 70:4, 547-553
CrossRef251
Steven Fishbane, Ajay K Singh. (2009) Iron deficiency in non-dialysis chronic kidney disease. Kidney International 75:7, 752-754
CrossRef252
Thomas Rath, Robert A. Mactier, Thomas Weinreich, Armin W. Scherhag. (2009) Effectiveness and safety of recombinant human erythropoietin beta in maintaining common haemoglobin targets in routine clinical practice in Europe: the GAIN study. Current Medical Research and Opinion 25:4, 961-970
CrossRef253
Donald S. Silverberg, Dov Wexler, Adrian Iaina, Doron Schwartz. (2009) The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions. Clinical and Experimental Nephrology 13:2, 101-106
CrossRef254
Steven Fishbane. (2009) Anemia in chronic kidney disease: status of new therapies. Current Opinion in Nephrology and Hypertension 18:2, 112-115
CrossRef255
MICAH L THORP, ERIC S JOHNSON, XUIHAI YANG, AMANDA F PETRIK, ROBERT PLATT, DAVID H SMITH. (2009) Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology 14:2, 240-246
CrossRef256
Gregory M. T. Hare, James E. Baker, C. David Mazer. (2009) Perioperative management of acute and chronic anemia: has the pendulum swung too far?. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 56:3, 183-189
CrossRef257
Claire Limrick, Coral McNichols-Thomas. (2009) ANAEMIA AND MINERAL BONE DISORDER IN CHRONIC KIDNEY DISEASE: A REVIEW OF THE CURRENT LITERATURE AND IMPLICATIONS FOR CLINICAL NURSING PRACTICE. Journal of Renal Care 35, 94-100
CrossRef258
Kamyar Kalantar-Zadeh, Elani Streja, Jessica E. Miller, Allen R. Nissenson. (2009) Intravenous Iron Versus Erythropoiesis-Stimulating Agents: Friends or Foes in Treating Chronic Kidney Disease Anemia?. Advances in Chronic Kidney Disease 16:2, 143-151
CrossRef259
Isabelle Von Kohorn, Richard A. Ehrenkranz. (2009) Anemia in the Preterm Infant: Erythropoietin Versus Erythrocyte Transfusion—It's not that Simple. Clinics in Perinatology 36:1, 111-123
CrossRef260
Susan T. Crowley, Aldo J. Peixoto. (2009) Acute Kidney Injury in the Intensive Care Unit. Clinics in Chest Medicine 30:1, 29-43
CrossRef261
Jalal K Ghali. (2009) Anemia and heart failure. Current Opinion in Cardiology 24:2, 172-178
CrossRef262
Anatole Besarab, Stanley Frinak, Jerry Yee. (2009) What Is So Bad About a Hemoglobin Level of 12 to 13 g/dL for Chronic Kidney Disease Patients Anyway?. Advances in Chronic Kidney Disease 16:2, 131-142
CrossRef263
Andrew C. Miller, Brandon Smaglo, Samy I. McFarlane. (2009) Obesity, anemia, and cardiovascular risk in patients with chronic kidney disease: Overview and pathophysiologic insights. Current Cardiovascular Risk Reports 3:2, 102-108
CrossRef264
Sai Ram Keithi-Reddy, Ajay K. Singh. (2009) Hemoglobin target in chronic kidney disease: a pediatric perspective. Pediatric Nephrology 24:3, 431-434
CrossRef265
Jay B. Wish. (2009) Past, Present, and Future of Chronic Kidney Disease Anemia Management in the United States. Advances in Chronic Kidney Disease 16:2, 101-108
CrossRef266
S. Charriere, N. Rognant, F. Chiche, A. Cremer, G. Deray, M. Priou. (2009) Insuffisance rénale chronique et maladie cardiovasculaire. Annales de Cardiologie et d'Angéiologie 58:1, 40-52
CrossRef267
Alejandro Macchia, Javier Mariani, Pablo Dino Comignani, Juan José Fuselli, Simona Monte, Marilena Romero, Gianni Tognoni. (2009) Anemia and chronic heart failure: from pathophysiologic mechanisms to clinical trial designs. Expert Review of Cardiovascular Therapy 7:2, 139-145
CrossRef268
Steven Fishbane. (2009) Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective. Kidney International 75:4, 358-365
CrossRef269
Amir Kazory, Edward A. Ross. (2009) Anemia: The Point of Convergence or Divergence for Kidney Disease and Heart Failure?. Journal of the American College of Cardiology 53:8, 639-647
CrossRef270
N. M. Paige, G. T. Nagami. (2009) The Top 10 Things Nephrologists Wish Every Primary Care Physician Knew. Mayo Clinic Proceedings 84:2, 180-186
CrossRef271
Csaba P. Kovesdy, Kamyar Kalantar-Zadeh. (2009) Why Is Protein–Energy Wasting Associated With Mortality in Chronic Kidney Disease?. Seminars in Nephrology 29:1, 3-14
CrossRef272
Vijayalakshmi Kunadian, Cafer Zorkun, William J. Gibson, Navin Nethala, Caitlin Harrigan, Alexandra M. Palmer, Katherine J. Ogando, Leah H. Biller, Erin E. Lord, Scott P. Williams, Michelle E. Lew, Lauren N. Ciaglo, Jacqueline L. Buros, Susan J. Marble, C. Michael Gibson. (2009) Transfusion associated microchimerism: a heretofore little recognized complication following transfusion. Journal of Thrombosis and Thrombolysis 27:1, 57-67
CrossRef273
A. L. M. de Francisco. (2009) Key insights into present and future treatments of anaemia in CKD patients. NDT Plus 2:Supplement 1, i1-i2
CrossRef274
Charles L. Bennett, Pamela S. Becker, Eric H. Kraut, Athena T. Samaras, Dennis P. West. (2009) Intersecting Guidelines: Administering Erythropoiesis-Stimulating Agents to Chronic Kidney Disease Patients with Cancer. Seminars in Dialysis 22:1, 1-4
CrossRef275
John V Terrovitis, Maria Anastasiou-Nana, Elissavet Kaldara, Stavros G Drakos, Serafeim N Nanas, John N Nanas. (2009) Anemia in heart failure: pathophysiologic insights and treatment options. Future Cardiology 5:1, 71-81
CrossRef276
Michael Hecht Olsen, Kristian Wachtell, Gareth Beevers, Björn Dahlöf, Richard B. Devereux, Ulf de Faire, Frej Fyhrquist, Hans Ibsen, Sverre E. Kjeldsen, Ole Lederballe-Pedersen, Lars H. Lindholm, Puneet Narayan, Markku S. Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel. (2009) Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Losartan Intervention For End point reduction in hypertension (LIFE) study. American Heart Journal 157:1, 177-184
CrossRef277
Ferdinand H Bahlmann, Danilo Fliser. (2009) Erythropoietin and renoprotection. Current Opinion in Nephrology and Hypertension 18:1, 15-20
CrossRef278
A. L. M. de Francisco, P. Stenvinkel, S. Vaulont. (2009) Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus 2:Supplement 1, i18-i26
CrossRef279
Eduardo Lacson, Weiling Wang, Raymond M. Hakim, Ming Teng, J. Michael Lazarus. (2009) Associates of Mortality and Hospitalization in Hemodialysis: Potentially Actionable Laboratory Variables and Vascular Access. American Journal of Kidney Diseases 53:1, 79-90
CrossRef280
Daniel W. Coyne. (2009) Managing Anemia in For-Profit Dialysis Chains: When Ethics and Business Conflict. Seminars in Dialysis 22:1, 18-21
CrossRef281
Ajay Singh. (2009) Hemoglobin Control, ESA Resistance, and Regular Low-Dose IV Iron Therapy: A Review of the Evidence. Seminars in Dialysis 22:1, 64-69
CrossRef282
S. D. Anker, R. Toto. (2009) Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients. NDT Plus 2:Supplement 1, i3-i8
CrossRef283
Anne M.S. Belonje, B. Daan Westenbrink, Adriaan A. Voors, Stephan von Haehling, Pjotr Ponikowski, Stefan D. Anker, Dirk J. van Veldhuisen, Kenneth Dickstein. (2009) Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan. American Heart Journal 157:1, 91-96
CrossRef284
M. R. Silver, R. Geronemus, M. Krause, C. Y. Chen, R. Kewalramani, C. Stehman-Breen. (2009) Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents*. Current Medical Research and Opinion 25:1, 123-131
CrossRef285
Sanae Hamaguchi, Miyuki Tsuchihashi-Makaya, Shintaro Kinugawa, Takashi Yokota, Akira Takeshita, Hisashi Yokoshiki, Hiroyuki Tsutsui, The JCARE-CARD Investigators. (2009) Anemia is an Independent Predictor of Long-Term Adverse Outcomes in Patients Hospitalized With Heart Failure in Japan. Circulation Journal 73:10, 1901-1908
CrossRef286
David E Leaf, David S Goldfarb. (2009) Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney International 75:1, 15-24
CrossRef287
Ajay K. Singh, Tejas Patel, Shona Pendse, Sairam Keithi-Reddy. 2009. Erythropoietin, Anemia and Kidney Disease. , 49-60.
CrossRef288
Iain C. Macdougall. 2009. Development of Recombinant Erythropoietin and Erythropoietin Analogs. , 35-48.
CrossRef289
N. D. Vaziri, X. J. Zhou. (2008) Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrology Dialysis Transplantation 24:4, 1082-1088
CrossRef290
Garry J. Handelman, Nathan W. Levin. (2008) Iron and anemia in human biology: a review of mechanisms. Heart Failure Reviews 13:4, 393-404
CrossRef291
Sunil Bhandari, Sarah Naudeer. (2008) Improving efficiency and value in health care
Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice. Journal of Evaluation in Clinical Practice 14:6, 996-1001
CrossRef292
Steve Elliott, Elizabeth Pham, Iain C. Macdougall. (2008) Erythropoietins: A common mechanism of action. Experimental Hematology 36:12, 1573-1584
CrossRef293
Ajay K. Singh. (2008) The Controversy Surrounding Hemoglobin and Erythropoiesis-Stimulating Agents: What Should We Do Now?. American Journal of Kidney Diseases 52:6, S5-S13
CrossRef294
Hassan N. Ibrahim, Areef Ishani, Robert N. Foley, Haifeng Guo, Jiannong Liu, Allan J. Collins. (2008) Temporal Trends in Red Blood Transfusion Among US Dialysis Patients, 1992-2005. American Journal of Kidney Diseases 52:6, 1115-1121
CrossRef295
José M Portolés, Ángel L M de Francisco, José L Górriz, Alberto Martínez-Castelao, Juan M López-Gómez, Manuel Arias, Juan J de la Cruz, Aleix Cases, Evaristo Fernández, Pedro Aljama. (2008) Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study. Kidney International 74, S82-S87
CrossRef296
Daniel W. Coyne. (2008) Introduction to “A Road Map for Intravenous Iron and Anemia Management: Preparing for the Future”. American Journal of Kidney Diseases 52:6, S1-S4
CrossRef297
Toros Kapoian. (2008) Challenge of Effectively Using Erythropoiesis-Stimulating Agents and Intravenous Iron. American Journal of Kidney Diseases 52:6, S21-S28
CrossRef298
Marc A. Pfeffer. (2008) Anemia treatment in chronic kidney disease: shifting uncertainty. Heart Failure Reviews 13:4, 425-430
CrossRef299
Robert N. Foley. (2008) Erythropoietin: physiology and molecular mechanisms. Heart Failure Reviews 13:4, 405-414
CrossRef300
Constance Tom Noguchi, Li Wang, Heather M. Rogers, Ruifeng Teng, Yi Jia. (2008) Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Reviews in Molecular Medicine 10,
CrossRef301
DONALD S. SILVERBERG, DOV WEXLER, ADRIAN IAINA, DORON SCHWARTZ. (2008) Anemia, chronic renal disease and chronic heart failure: the cardiorenal anemia syndrome. Transfusion Alternatives in Transfusion Medicine 10:4, 189-196
CrossRef302
George Mak, Niamh F. Murphy, Kenneth McDonald. (2008) Anemia in heart failure: To treat or not to treat?. Current Treatment Options in Cardiovascular Medicine 10:6, 455-464
CrossRef303
Eric L Eisenstein. (2008) DRIVE it home: making the case for prospective economic data collection in randomized clinical trials. Kidney International 74:12, 1507-1509
CrossRef304
Jessica Kendrick, Michel B Chonchol. (2008) Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nature Clinical Practice Nephrology 4:12, 672-681
CrossRef305
Francesco Locatelli, Lucia Del Vecchio. (2008) Optimizing the management of renal anemia: challenges and new opportunities. Kidney International 74, S33-S37
CrossRef306
James S. Kaufman. (2008) Racial Differences in Erythropoietin Responsiveness. American Journal of Kidney Diseases 52:6, 1035-1038
CrossRef307
B. Radbill, B. Murphy, D. LeRoith. (2008) Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease. Mayo Clinic Proceedings 83:12, 1373-1381
CrossRef308
James E Novak, Lynda A Szczech. (2008) Triumph and tragedy: anemia management in chronic kidney disease. Current Opinion in Nephrology and Hypertension 17:6, 580-588
CrossRef309
M. Krzakowski. (2008) Epoetin Delta: Efficacy in the Treatment of Anaemia in Cancer Patients Receiving Chemotherapy. Clinical Oncology 20:9, 705-713
CrossRef310
Uptal D. Patel, Joshua Grab, Mikhail Kosiborod, Barbara Lytle MS, Eric D. Peterson, Karen P. Alexander. (2008) Impact of Anemia on Physical Function and Survival Among Patients with Coronary Artery Disease. Clinical Cardiology 31:11, 546-550
CrossRef311
Georgene W. Hergenroeder, Robert L. Levine, Charles C. Miller. (2008) Thromboembolism Prophylaxis in End-Stage Renal Disease. Dialysis & Transplantation 37:11, 439-444
CrossRef312
Francesco Locatelli, Allen R Nissenson, Brendan J Barrett, Rowan G Walker, David C Wheeler, Kai U Eckardt, Norbert H Lameire, Garabed Eknoyan. (2008) Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International 74:10, 1237-1240
CrossRef313
Andrea Luk, Juliana C.N. Chan. (2008) Diabetic nephropathy—What are the unmet needs?. Diabetes Research and Clinical Practice 82, S15-S20
CrossRef314
B. Canaud, G. Mingardi, J. Braun, P. Aljama, P. G. Kerr, F. Locatelli, G. Villa, B. Van Vlem, A. W. McMahon, C. Kerloeguen, U. Beyer, . (2008) Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrology Dialysis Transplantation 23:11, 3654-3661
CrossRef315
James E Novak, Jula K Inrig, Uptal D Patel, Robert M Califf, Lynda A Szczech. (2008) Negative trials in nephrology: what can we learn?. Kidney International 74:9, 1121-1127
CrossRef316
Steven Fishbane. (2008) Anemia and Cardiovascular Risk in the Patient with Kidney Disease. Heart Failure Clinics 4:4, 401-410
CrossRef317
Ali Ahmed, Ruth C. Campbell. (2008) Epidemiology of Chronic Kidney Disease in Heart Failure. Heart Failure Clinics 4:4, 387-399
CrossRef318
T.J. Littlewood. (2008) Normalization of Hemoglobin in Patients With CKD May Cause Harm: But What Is the Mechanism?. American Journal of Kidney Diseases 52:4, 642-644
CrossRef319
Andrew S. Artz. (2008) Anemia and the Frail Elderly. Seminars in Hematology 45:4, 261-266
CrossRef320
Paulo H.M. Chaves. (2008) Functional Outcomes of Anemia in Older Adults. Seminars in Hematology 45:4, 255-260
CrossRef321
Cataldo Abaterusso, Nicoletta Pertica, Antonio Lupo, Vittorio Ortalda, Giovanni Gambaro. (2008) Anaemia in diabetic renal failure: is there a role for early erythropoietin treatment in preventing cardiovascular mortality?. Diabetes, Obesity and Metabolism 10:10, 843-849
CrossRef322
Kwame Asare. (2008) Anemia of Critical Illness. Pharmacotherapy 28:10, 1267-1282
CrossRef323
Elani Streja, Csaba P. Kovesdy, Sander Greenland, Joel D. Kopple, Charles J. McAllister, Allen R. Nissenson, Kamyar Kalantar-Zadeh. (2008) Erythropoietin, Iron Depletion, and Relative Thrombocytosis: A Possible Explanation for Hemoglobin-Survival Paradox in Hemodialysis. American Journal of Kidney Diseases 52:4, 727-736
CrossRef324
Y. W. J. Sijpkens, N. C. Berkhout-Byrne, T. J. Rabelink. (2008) Optimal predialysis care. NDT Plus 1:Supplement 4, iv7-iv13
CrossRef325
A. Baglin, T. Hanslik, J. Prinseau, L. Moulonguet-Doleris. (2008) Érythropoïétine et insuffisance rénale : jusqu’où ne pas aller ?. La Revue de Médecine Interne 29:10, 846-851
CrossRef326
Zoltán Kiss, Imre Kulcsár, István Kiss. (2008) Hemoglobinvariabilitás krónikus veseelégtelenségben szenvedő betegekben. Orvosi Hetilap 149:41, 1925-1934
CrossRef327
Thai Nguyen, Robert D. Toto. (2008) Slowing chronic kidney disease progression: results of prospective clinical trials in adults. Pediatric Nephrology 23:9, 1409-1422
CrossRef328
Ajay K Singh, Edgar Milford, Steven Fishbane, Sai Ram Keithi-Reddy. (2008) Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney International 74:5, 679-683
CrossRef329
Mitchell H Rosner, W Kline Bolton. (2008) The mortality risk associated with higher hemoglobin: is the therapy to blame?. Kidney International 74:6, 695-697
CrossRef330
Hessel F. Groenveld, James L. Januzzi, Kevin Damman, Jan van Wijngaarden, Hans L. Hillege, Dirk J. van Veldhuisen, Peter van der Meer. (2008) Anemia and Mortality in Heart Failure Patients. Journal of the American College of Cardiology 52:10, 818-827
CrossRef331
Charles J. Diskin, Thomas J. Stokes, Linda M. Dansby, Lautrec Radcliff, Thomas B. Carter. (2008) Beyond Anemia: The Clinical Impact of the Physiologic Effects of Erythropoietin. Seminars in Dialysis 21:5, 447-454
CrossRef332
Kitty J Jager, Paul C van Dijk, Carmine Zoccali, Friedo W Dekker. (2008) The analysis of survival data: the Kaplan–Meier method. Kidney International 74:5, 560-565
CrossRef333
Sai Ram Keithi-Reddy, Francesco Addabbo, Tejas V Patel, Bharati V Mittal, Michael S Goligorsky, Ajay K Singh. (2008) Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney International 74:6, 782-790
CrossRef334
Daniel W. Coyne. (2008) The TREAT Study Answers a Question, Not the Question. American Journal of Kidney Diseases 52:3, 626-627
CrossRef335
Lynda A Szczech, Huiman X Barnhart, Jula K Inrig, Donal N Reddan, Shelly Sapp, Robert M Califf, Uptal D Patel, Ajay K Singh. (2008) Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney International 74:6, 791-798
CrossRef336
NEIL SONI, BENJAMIN THOMAS. (2008) The benefits of allogeneic erythrocyte transfusion: what evidence do we have?. Transfusion Alternatives in Transfusion Medicine 10:3, 147-159
CrossRef337
Nosratola D Vaziri. (2008) Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease?. Nature Clinical Practice Nephrology 4:8, 436-445
CrossRef338
Braden J Manns, Colin T White, Francois Madore, Louise M Moist, Scott W Klarenbach, Brendan J Barrett, Rob N Foley, Bruce F Culleton, Marcello Tonelli. (2008) Introduction to the Canadian Society of Nephrology Clinical Practice Guidelines for the management of anemia associated with chronic kidney disease. Kidney International 74, S1-S3
CrossRef339
KRISHAN K MADHAN, MICHELLE CHAMBERLAIN, ELIZABETH ANDERSON. (2008) Anaemia in patients with chronic kidney disease: Management with epoetin beta in primary care setting in New Zealand. Nephrology 13:5, 428-432
CrossRef340
Ferdinand H. Bahlmann. (2008) Use of Erythropoietin for Cardiovascular Protection. Cardiovascular Drugs and Therapy 22:4, 253-255
CrossRef341
Manisha Jhamb, Steven D. Weisbord, Jennifer L. Steel, Mark Unruh. (2008) Fatigue in Patients Receiving Maintenance Dialysis: A Review of Definitions, Measures, and Contributing Factors. American Journal of Kidney Diseases 52:2, 353-365
CrossRef342
B. Daan Westenbrink, Hisko Oeseburg, Lennaert Kleijn, Pim Harst, Anne M. S. Belonje, Adriaan A. Voors, Regien G. Schoemaker, Rudolf A. Boer, Dirk J. Veldhuisen, Wiek H. Gilst. (2008) Erythropoietin Stimulates Normal Endothelial Progenitor Cell-Mediated Endothelial Turnover, but Attributes to Neovascularization Only in the Presence of Local Ischemia. Cardiovascular Drugs and Therapy 22:4, 265-274
CrossRef343
Louise M Moist, Rob N Foley, Brendan J Barrett, Francois Madore, Colin T White, Scott W Klarenbach, Bruce F Culleton, Marcello Tonelli, Braden J Manns. (2008) Clinical Practice Guidelines for evidence-based use of erythropoietic-stimulating agents. Kidney International 74, S12-S18
CrossRef344
Inder S. Anand. (2008) Anemia and Chronic Heart Failure. Journal of the American College of Cardiology 52:7, 501-511
CrossRef345
Jason Moore, Xiang He, Paul Cockwell, Mark A. Little, Atholl Johnston, Richard Borrows. (2008) The Impact of Hemoglobin Levels on Patient and Graft Survival in Renal Transplant Recipients. Transplantation 86:4, 564-570
CrossRef346
Lawrence McMahon. (2008) Haemoglobin. Nephrology 13, S44-S56
CrossRef347
Dick de Zeeuw. (2008) Renal disease: a common and a silent killer. Nature Clinical Practice Cardiovascular Medicine 5, S27-S35
CrossRef348
Sean A. Virani, Amit Khosla, Adeera Levin. (2008) Chronic kidney disease, heart failure and anemia. Canadian Journal of Cardiology 24, 22B-24B
CrossRef349
S. Summers, S. Holdsworth, E. Sharples. (2008) The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia. Nephrology Dialysis Transplantation 23:10, 3053-3055
CrossRef350
T. J. Littlewood, R. Alikhan. (2008) The use of intravenous iron in patients with cancer-related anaemia. British Journal of Haematology 141:6, 751-756
CrossRef351
Samina Khan, Chester A. Amedia. (2008) Economic burden of chronic kidney disease. Journal of Evaluation in Clinical Practice 14:3, 422-434
CrossRef352
K. Maekawa, T. Shoji, M. Emoto, S. Okuno, T. Yamakawa, E. Ishimura, M. Inaba, Y. Nishizawa. (2008) Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. Nephrology Dialysis Transplantation 23:7, 2329-2336
CrossRef353
Willem-Peter T. Ruifrok, Rudolf A. de Boer, B. Daan Westenbrink, Dirk J. van Veldhuisen, Wiek H. van Gilst. (2008) Erythropoietin in cardiac disease: New features of an old drug. European Journal of Pharmacology 585:2-3, 270-277
CrossRef354
Elke Wühl, Franz Schaefer. (2008) Therapeutic strategies to slow chronic kidney disease progression. Pediatric Nephrology 23:5, 705-716
CrossRef355
Stein Ivar Hallan, Bjørn Egil Vikse. (2008) Relationship between chronic kidney disease prevalence and end-stage renal disease risk. Current Opinion in Nephrology and Hypertension 17:3, 286-291
CrossRef356
Wolfgang Jelkmann. (2008) Developments in the therapeutic use of erythropoiesis stimulating agents. British Journal of Haematology 141:3, 287-297
CrossRef357
Anne M. Belonje, Adriaan A. Voors, Wiek H. van Gilst, Stefan D. Anker, Riemer H. Slart, Rene A. Tio, Felix Zijlstra, Dirk J. van Veldhuisen. (2008) Effects of erythropoietin after an acute myocardial infarction: Rationale and study design of a prospective, randomized, clinical trial (HEBE III). American Heart Journal 155:5, 817-822
CrossRef358
Naomi V. Dahl, David H. Henry, Daniel W. Coyne. (2008) Editorial Focus: Thrombosis with Erythropoietic Stimulating Agents-Does Iron-Deficient Erythropoiesis Play a Role?. Seminars in Dialysis 21:3, 210-211
CrossRef359
Albert Lam, Siddharth Shah, James Paparello. (2008) Outpatient Management of Chronic Kidney Disease: Proteinuria, Anemia and Bone Disease as Therapeutic Targets. American Journal of Therapeutics 15:3, 278-286
CrossRef360
Daniel W. Coyne. (2008) From Anemia Trials to Clinical Practice: Understanding the Risks and Benefits When Setting Goals for Therapy. Seminars in Dialysis 21:3, 212-216
CrossRef361
Anil K Agarwal. (2008) Darbepoetin alfa for anemia in chronic kidney disease. Expert Review of Clinical Pharmacology 1:3, 369-379
CrossRef362
Simon Ficht, Richard J. Payne, Richard T. Guy, Chi-Huey Wong. (2008) Solid-Phase Synthesis of Peptide and Glycopeptide Thioesters through Side-Chain-Anchoring Strategies. Chemistry - A European Journal 14:12, 3620-3629
CrossRef363
M. Chonchol, G. Lippi, M. Montagnana, M. Muggeo, G. Targher. (2008) Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. Nephrology Dialysis Transplantation 23:9, 2879-2883
CrossRef364
K. E. Chan, R. A. Lafayette, A. S. Whittemore, M. A. Hlatky, J. Moran. (2008) Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrology Dialysis Transplantation 23:9, 2948-2956
CrossRef365
D. W. Swinkels, J. F. M. Wetzels. (2008) Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. Nephrology Dialysis Transplantation 23:8, 2450-2453
CrossRef366
G. Schlieper, M. Hristov, V. Brandenburg, T. Kruger, R. Westenfeld, A. H. Mahnken, E. Yagmur, G. Boecker, N. Heussen, U. Gladziwa, M. Ketteler, C. Weber, J. Floege. (2008) Predictors of low circulating endothelial progenitor cell numbers in haemodialysis patients. Nephrology Dialysis Transplantation 23:8, 2611-2618
CrossRef367
Martin Dunkelgrun, Sanne E. Hoeks, Gijs M.J.M. Welten, Radosav Vidakovic, Tamara A. Winkel, Olaf Schouten, Ron T. van Domburg, Jeroen J. Bax, Ruud Kuijper, Michael Chonchol, Hence J.M. Verhagen, Don Poldermans. (2008) Anemia as an Independent Predictor of Perioperative and Long-Term Cardiovascular Outcome in Patients Scheduled for Elective Vascular Surgery. The American Journal of Cardiology 101:8, 1196-1200
CrossRef368
Dhruv K Singh, Peter Winocour, Ken Farrington. (2008) Mechanisms of Disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nature Clinical Practice Nephrology 4:4, 216-226
CrossRef369
Murat O. Arcasoy. (2008) The non-haematopoietic biological effects of erythropoietin. British Journal of Haematology 141:1, 14-31
CrossRef370
Adeera Levin. (2008) Management of anemia with intravenous methoxy polyethylene glycol–epoetin beta in patients on dialysis. Nature Clinical Practice Nephrology 4:4, 186-187
CrossRef371
Joel Michels Topf. (2008) CERA: third-generation erythropoiesis-stimulating agent. Expert Opinion on Pharmacotherapy 9:5, 839-849
CrossRef372
Y. A. Minamishima, J. Moslehi, N. Bardeesy, D. Cullen, R. T. Bronson, W. G. Kaelin. (2008) Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 111:6, 3236-3244
CrossRef373
Volker Wizemann, Boleslaw Rutkowski, Conrad Baldamus, Paul Scigalla, Rossen Koytchev. (2008) Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Current Medical Research and Opinion 24:3, 625-637
CrossRef374
Umesh Tamhane, John Voytas, Rabeea Aboufakher, Michael Maddens. (2008) Do Hemoglobin and Creatinine Clearance Affect Hospital Readmission Rates from a Skilled Nursing Facility Heart Failure Rehabilitation Unit?. Journal of the American Medical Directors Association 9:3, 194-198
CrossRef375
A Mohanram, Z Zhang, S Shahinfar, P A Lyle, R D Toto. (2008) The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney International 73:5, 630-636
CrossRef376
B Daan Westenbrink, Rudolf A de Boer, Adriaan A Voors, Wiek H van Gilst, Dirk J van Veldhuisen. (2008) Anemia in chronic heart failure: etiology and treatment options. Current Opinion in Cardiology 23:2, 141-147
CrossRef377
Michel Chonchol, Christopher Nielson. (2008) Hemoglobin levels and coronary artery disease. American Heart Journal 155:3, 494-498
CrossRef378
TJ Littlewood, GP Collins. (2008) Pharmacotherapy of anemia in cancer patients. Expert Review of Clinical Pharmacology 1:2, 307-317
CrossRef379
R.M. Schaefer, L. Schaefer. (2008) Eisen- und ESA*-Therapie bei renaler Anämie. Der Nephrologe 3:2, 88-95
CrossRef380
M. Ketteler. (2008) Phosphatbinder, Vitamin D, Cinacalcet. Der Nephrologe 3:2, 96-107
CrossRef381
Dana Saffel, T. S. Dharmarajan, Michael J. Germain. (2008) Practical Strategies for Improving Anemia Management in the Elderly. The Consultant Pharmacist 23:0, 1-25
CrossRef382
Marc A. Pfeffer. (2008) Critical Missing Data on Erythropoiesis-Stimulating Agents in CKD: First Beat Placebo. American Journal of Kidney Diseases 51:3, 366-369
CrossRef383
Michael R. Savona, Samuel M. Silver. (2008) Erythropoietin-Stimulating Agents in Oncology. The Cancer Journal 14:2, 75-84
CrossRef384
John H. Powers. (2008) Noninferiority and equivalence trials: deciphering ‘similarity’ of medical interventions. Statistics in Medicine 27:3, 343-352
CrossRef385
Baqiyyah Conway, Linda Fried, Tevor Orchard. (2008) Hemoglobin and Overt Nephropathy Complications in Type 1 Diabetes. Annals of Epidemiology 18:2, 147-155
CrossRef386
A. M. S. Belonje, R. A. Boer, A. A. Voors. (2008) Recombinant Human Epo Treatment: Beneficial in Chronic Kidney Disease, Chronic Heart Failure, or Both?. Cardiovascular Drugs and Therapy 22:1, 1-2
CrossRef387
Konstantinos D. Pappas, Chariklia D. Gouva, Konstantinos P. Katopodis, Petros M. Nikolopoulos, Panagiotis G. Korantzopoulos, Lampros K. Michalis, John A. Goudevenos, Kostas C. Siamopoulos. (2008) Correction of Anemia with Erythropoietin in Chronic Kidney Disease (stage 3 or 4): Effects on Cardiac Performance. Cardiovascular Drugs and Therapy 22:1, 37-44
CrossRef388
W.H. Wilson Tang, Wilson Tong, Anil Jain, Gary S. Francis, C. Martin Harris, James B. Young. (2008) Evaluation and Long-Term Prognosis of New-Onset, Transient, and Persistent Anemia in Ambulatory Patients With Chronic Heart Failure. Journal of the American College of Cardiology 51:5, 569-576
CrossRef389
D Cotter, Y Zhang, M Thamer, J Kaufman, M A Hernán. (2008) The effect of epoetin dose on hematocrit. Kidney International 73:3, 347-353
CrossRef390
A Palumbo, S V Rajkumar, M A Dimopoulos, P G Richardson, J San Miguel, B Barlogie, J Harousseau, J A Zonder, M Cavo, M Zangari, M Attal, A Belch, S Knop, D Joshua, O Sezer, H Ludwig, D Vesole, J Bladé, R Kyle, J Westin, D Weber, S Bringhen, R Niesvizky, A Waage, M von Lilienfeld-Toal, S Lonial, G J Morgan, R Z Orlowski, K Shimizu, K C Anderson, M Boccadoro, B G Durie, P Sonneveld, M A Hussein. (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:2, 414-423
CrossRef391
Jonathan G Howlett. (2008) Recognition and treatment of anemia in the setting of heart failure due to systolic left ventricular dysfunction. Expert Review of Cardiovascular Therapy 6:2, 199-208
CrossRef392
K J Jager, C Zoccali, A MacLeod, F W Dekker. (2008) Confounding: What it is and how to deal with it. Kidney International 73:3, 256-260
CrossRef393
Besarab, Anatole, , Goodkin, David A., Nissenson, Allen R., . (2008) The Normal Hematocrit Study — Follow-up. New England Journal of Medicine 358:4, 433-434
Full Text394
James B. Young, William T. Abraham, Nancy M. Albert, Wendy Gattis Stough, Mihai Gheorghiade, Barry H. Greenberg, Christopher M. O’Connor, Lilin She, Jie Lena Sun, Clyde W. Yancy, Gregg C. Fonarow. (2008) Relation of Low Hemoglobin and Anemia to Morbidity and Mortality in Patients Hospitalized With Heart Failure (Insight from the OPTIMIZE-HF Registry). The American Journal of Cardiology 101:2, 223-230
CrossRef395
Ajay K. Singh, Steven Fishbane. (2008) Editorial: The Optimal Hemoglobin in Dialysis Patients- A Critical Review. Seminars in Dialysis 21:1, 1-6
CrossRef396
William E. Braun. 2008. Cardiovascular and Other Noninfectious Complications after Renal Transplantation in Adults. , 1009-1033.
CrossRef397
Yves F.C. Vanrenterghem, Kathleen Claes, Giuseppe Montagnino, Steffen Fieuws, Bart Maes, Margarita Villa, Claudio Ponticelli. (2008) Risk Factors for Cardiovascular Events After Successful Renal Transplantation. Transplantation 85:2, 209-216
CrossRef398
Giuseppe Remuzzi, Luigi Minetti, Arrigo Schieppati. 2008. Treatment of Anemia and Bleeding in Chronic Kidney Disease. , 756-764.
CrossRef399
Robert E. Schmidt, Karen G. Green, Dongyan Feng, Denise A. Dorsey, Curtis A. Parvin, Jin-Moo Lee, Qinlgi Xiao, Michael Brines. (2008) Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice. Experimental Neurology 209:1, 161-170
CrossRef400
Dede Sit, Ali Kemal Kadiroglu, Hasan Kayabasi, Ismail Hamdi Kara, Zulfukar Yilmaz, M. Emin Yilmaz. (2008) The Evaluation Incidence and Risk Factors of Mortality among Patients with End Stage Renal Disease in Southeast Turkey. Renal Failure 30:1, 37-44
CrossRef401
Karien van der Putten, Branko Braam, Kim E Jie, Carlo AJM Gaillard. (2008) Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. Nature Clinical Practice Nephrology 4:1, 47-57
CrossRef402
David Goldsmith. (2008) Negative Outcome Studies in End-Stage Renal Disease. Blood Purification 26:1, 63-66
CrossRef403
Robert E. Blaser, Alan S. Kliger. (2008) Congressional Oversight of Medicare Program Intensifies: A Look at the Factors Surrounding the Scrutiny and Nephrology's Response. Advances in Chronic Kidney Disease 15:1, 10-14
CrossRef404
P.E. Stevens. (2008) Blind Pew Sends a Black Spot: The Current Haemoglobin Controversy. Blood Purification 26:1, 54-58
CrossRef405
Steven D. WEISBORD, Paul L. KIMMEL. (2008) Health-related quality of life in the era of erythropoietin. Hemodialysis International 12:1, 6-15
CrossRef406
Steven Fishbane. 2008. Iron and Erythropoietin-Related Therapies. , 749-755.
CrossRef407
Kim Buettner, Stephen Z. Fadem. (2008) The Internet as a Tool for the Renal Community. Advances in Chronic Kidney Disease 15:1, 73-82
CrossRef408
Ramnath Dukkipati, Sharon Adler, Rajnish Mehrotra. (2008) Cardiovascular Implications of Chronic Kidney Disease in Older Adults. Drugs & Aging 25:3, 241-253
CrossRef409
Eberhard Ritz, Christoph Wanner. 2008. Cardiovascular Complications of End-Stage Renal Disease. , 773-782.
CrossRef410
Lucia Del Vecchio, Andrea Cavalli, Pietro Pozzoni, Francesco Locatelli. (2008) Recombinant human epoetin beta in the treatment of renal anemia. Therapy 5:1, 91-98
CrossRef411
Nathalie Thilly, Bénédicte Stengel, Stéphanie Boini, Emmanuel Villar, Cécile Couchoud, Luc Frimat. (2008) Evaluation and Determinants of Underprescription of Erythropoiesis Stimulating Agents in Pre-Dialysis Patients with Anaemia. Nephron Clinical Practice 108:1, c67-c74
CrossRef412
Monique P Curran, Paul L McCormack. (2008) Methoxy Polyethylene Glycol-Epoetin Beta. Drugs 68:8, 1139-1156
CrossRef413
Richard Amerling, James F. Winchester, Claudio Ronco. (2008) Guidelines Have Done More Harm than Good. Blood Purification 26:1, 73-76
CrossRef414
Peter B. DeOreo. (2008) The Role of Medical Directors in Dialysis Facilities
CrossRef415
(2008) 2008 JSDT “Guideline for Renal Anemia in Chronic Kidney Disease”. Nihon Toseki Igakkai Zasshi 41:10, 661-716
CrossRef416
Adam E. Gaweda, Alfred A. Jacobs, George R. Aronoff, Michael E. Brier. (2008) Model Predictive Control of Erythropoietin Administration in the Anemia of ESRD. American Journal of Kidney Diseases 51:1, 71-79
CrossRef417
Catherine Blake, William D. Plant. 2008. Measures to Improve Quality of Life in End-Stage Renal Disease Patients. , 818-827.
CrossRef418
Marcus Alexander, Reshma Kewalramani, Irene Agodoa, Denise Globe. (2007) Association of anemia correction with health related quality of life in patients not on dialysis*. Current Medical Research and Opinion 23:12, 2997-3008
CrossRef419
Ajay K Singh. (2007) Does correction of anemia slow the progression of chronic kidney disease?. Nature Clinical Practice Nephrology 3:12, 638-639
CrossRef420
Irina Stoian, Bogdan Manolescu, Valeriu Atanasiu, Olivera Lupescu. (2007) New alternatives for erythropoietin therapy in chronic renal failure. Central European Journal of Medicine 2:4, 361-378
CrossRef421
Angela Dispenzieri. (2007) Complications of Myeloma Therapy. Hematology/Oncology Clinics of North America 21:6, 1247-1273
CrossRef422
Jan N. Basile. (2007) Clinical Considerations and Practical Recommendations for the Primary Care Practitioner in the Management of Anemia of Chronic Kidney Disease. Southern Medical Journal 100:12, 1200-1207
CrossRef423
R Vanholder, H Vanbelleghem, N Lameire, G Eknoyan. (2007) Response to ‘Hemoglobin level in dialysis patients: Revisiting the normal hematocrit study’. Kidney International 72:9, 1161-1162
CrossRef424
K Iseki, K Kohagura. (2007) Anemia as a risk factor for chronic kidney disease. Kidney International 72, S4-S9
CrossRef425
Vivien M. Hodges, Susan Rainey, Terence R. Lappin, A. Peter Maxwell. (2007) Pathophysiology of anemia and erythrocytosis. Critical Reviews in Oncology/Hematology 64:2, 139-158
CrossRef426
J. B. Wish, D. W. Coyne. (2007) Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations of Existing Therapies. Mayo Clinic Proceedings 82:11, 1371-1380
CrossRef427
M Nangaku, D Fliser. (2007) Erythropoiesis-stimulating agents: Past and future. Kidney International 72, S1-S3
CrossRef428
Z Aydin, J Duijs, I M Bajema, A J van Zonneveld, T J Rabelink. (2007) Erythropoietin, progenitors, and repair. Kidney International 72, S16-S20
CrossRef429
F H Bahlmann, J T Kielstein, H Haller, D Fliser. (2007) Erythropoietin and progression of CKD. Kidney International 72, S21-S25
CrossRef430
Iain C Macdougall. (2007) Epoetin-induced pure red cell aplasia: diagnosis and treatment. Current Opinion in Nephrology and Hypertension 16:6, 585-588
CrossRef431
A K Singh. (2007) Hemoglobin level in dialysis patients: Revisiting the normal hematocrit study. Kidney International 72:9, 1161-1161
CrossRef432
Bonnie Ching-Ha Kwan, Cheuk-Chun Szeto. (2007) Management of Anemia in Dialysis Patients—The Whats and Hows. Hong Kong Journal of Nephrology 9:2, 55-57
CrossRef433
&NA;. (2007) Erythropoietin Safety Concerns. Obstetrics & Gynecology 110:4, 919-921
CrossRef434
S Fishbane, A R Nissenson. (2007) The new FDA label for erythropoietin treatment: How does it affect hemoglobin target?. Kidney International 72:7, 806-813
CrossRef435
C. Robert Valeri, Shukri Khuri, Gina Ragno. (2007) Nonsurgical bleeding diathesis in anemic thrombocytopenic patients: role of temperature, red blood cells, platelets, and plasma-clotting proteins. Transfusion 47:s4, 206S-248S
CrossRef436
Jorge Eduardo Toblli, Alejandra Lombraña, Patricio Duarte, Federico Di Gennaro. (2007) Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency. Journal of the American College of Cardiology 50:17, 1657-1665
CrossRef437
Gary S. Francis, Anne Kanderian. (2007) Anemia and Heart Failure. Journal of the American College of Cardiology 50:17, 1666-1667
CrossRef438
Bertram L. Kasiske. (2007) Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A US Physician Perspective. American Journal of Kidney Diseases 50:3, 354-357
CrossRef439
Daniel E. Weiner, Andrew S. Levey. (2007) Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: An Overview. American Journal of Kidney Diseases 50:3, 349-353
CrossRef440
N. Schub, U. Kunzendorf. (2007) Prognostische Bedeutung der Anämie nach Nierentransplantation. Der Nephrologe 2:5, 364-365
CrossRef441
Anne M.S. Belonje, Adriaan A. Voors, Wiek H. van Gilst, Dirk J. van Veldhuisen. (2007) Erythropoietin in Chronic Heart Failure. Congestive Heart Failure 13:5, 289-292
CrossRef442
Iain C. Macdougall. (2007) Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A View From Europe. American Journal of Kidney Diseases 50:3, 358-361
CrossRef443
J. Michael Lazarus, Raymond M. Hakim. (2007) Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective. American Journal of Kidney Diseases 50:3, 366-370
CrossRef444
Marianne L. Smebye, Emil K. Iversen, Aud Høieggen, Arnljot Flaa, Ingrid Os, Sverre E. Kjeldsen, Michael Hecht Olsen, Arghya Chattopadhyay, Darcy A. Hille, Paulette A. Lyle, Richard B. Devereux, Björn Dahlöf. (2007) Effect of Hemoglobin Levels on Cardiovascular Outcomes in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy (from the LIFE Study). The American Journal of Cardiology 100:5, 855-859
CrossRef445
(2007) KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. American Journal of Kidney Diseases 50:3, 471-530
CrossRef446
Carlos Caramelo, Soledad Justo, Paloma Gil. (2007) Anemia en la insuficiencia cardiaca: fisiopatología, patogenia, tratamiento e incógnitas. Revista Española de Cardiología 60:8, 848-860
CrossRef447
Ajay K Singh. (2007) Anemia of chronic kidney disease: CHOIR and the FDA. Nature Clinical Practice Nephrology 3:8, 406-407
CrossRef448
C. Anthony Blau. (2007) Erythropoietin in Cancer: Presumption of Innocence?. Stem Cells 25:8, 2094-2097
CrossRef449
Behdad Afzali, David JA Goldsmith. (2007) Long-term risks of increased use of intravenous iron. The Lancet 370:9586, 482
CrossRef450
Jeffrey Hymes, Tammy Bickimer, James H. Jackson, Brahim K. Bookhart, Samir H. Mody, Catherine Tak Piech. (2007) Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa. Current Medical Research and Opinion 23:8, 1931-1937
CrossRef451
Michael Auerbach, Harold Ballard, John Glaspy. (2007) Long-term risks of increased use of intravenous iron – Authors' reply. The Lancet 370:9586, 482-483
CrossRef452
P.A. Gladding, M.W. Webster, P. Kay. (2007) Late Drug-eluting Stent Thrombosis and Erythropoietin: Cause and Effect?. Heart, Lung and Circulation 16:4, 305-307
CrossRef453
Robert N. FOLEY, Rui ZHANG, David T. GILBERTSON, Stephan DUNNING, Areef ISHANI, Allan J. COLLINS. (2007) Exceeding hemoglobin target levels in US hemodialysis patients receiving epoetin, 1999 to 2002. Hemodialysis International 11:3, 333-339
CrossRef454
A J Kallen, P R Patel. (2007) In search of a rational approach to chronic kidney disease detection and management. Kidney International 72:1, 3-5
CrossRef455
C. Hasslacher. (2007) Protektion der Nierenfunktion bei Diabetikern. Der Internist 48:7, 686-697
CrossRef456
Gernot Beutel, Arnold Ganser. (2007) Risks and Benefits of Erythropoiesis-Stimulating Agents in Cancer Management. Seminars in Hematology 44:3, 157-165
CrossRef457
Adeera Levin. (2007) The treatment of anemia in chronic kidney disease: understandings in 2006. Current Opinion in Nephrology and Hypertension 16:3, 267-271
CrossRef458
Hiroshi Nonoguchi, Yushi Nakayama, Takeaki Inoue, Yukimasa Kohda, Kimio Tomita. (2007) Target haemoglobin concentrations in chronic kidney disease. The Lancet 369:9572, 1517
CrossRef459
Jeffrey S. Berns, Steven Fishbane. (2007) Summary and Comment: CHOIR, CREATE, and Anemia Treatment in Patients with CKD. Seminars in Dialysis 20:3, 277-279
CrossRef460
Ajay K. Singh. (2007) The target hemoglobin level in patients on dialysis. Dialysis & Transplantation 36:5, 284-286
CrossRef461
Laura M Dember. (2007) Anemia in patients with chronic kidney disease: defining the optimal hemoglobin target. Nature Clinical Practice Nephrology 3:5, 244-245
CrossRef462
Tilman B Drüeke. (2007) Target haemoglobin concentrations in chronic kidney disease. The Lancet 369:9572, 1516
CrossRef463
P. J. M. M. Toll’s-Hertogenbosch. (2007) Hoeveel erytropoëtine bij nierfalen? Tijd om de bakens te verzetten. Medisch-Farmaceutische Mededelingen 45:4, 101-102
CrossRef464
Michele B. Kaufman. (2007) Hemoglobin levels in CKD: What's the correct level?. Dialysis & Transplantation 36:4, 236-237
CrossRef465
M. R. Weir. (2007) Is Anemia a Predictor for Mortality and Loss of Graft Function in Kidney Transplant Recipients?. American Journal of Transplantation 7:4, 731-732
CrossRef466
Pfeffer, Marc A., . (2007) An Ongoing Study of Anemia Correction in Chronic Kidney Disease. New England Journal of Medicine 356:9, 959-961
Full Text467
(2007) Chronic Kidney Disease, Anemia, and Epoetin. New England Journal of Medicine 356:9, 956-959
Full Text468
Patrick S. Parfrey. (2007) In the Literature: On Clinical Performance Measures and Outcomes Among Hemodialysis Patients. American Journal of Kidney Diseases 49:3, 352-355
CrossRef469
Wolfgang Jelkmann. (2007) Erythropoietin after a century of research: younger than ever. European Journal of Haematology 78:3, 183-205
CrossRef470
Magdolna G. Sebestyén, Julia O. Hegge, Mark A. Noble, David L. Lewis, Hans Herweijer, Jon A. Wolff. (2007) Progress Toward A Nonviral Gene Therapy Protocol for The Treatment of Anemia. Human Gene Therapy 18:3, 269-285
CrossRef471
Holger Kristen. (2007) Welche Folgen hat die Normalisierung der Hämoglobinkonzentration bei Patienten mit chronischer Niereninsuffizienz und Anämie?. Der Nephrologe 2:2, 119-120
CrossRef472
Eberhard Ritz, Maurice Laville, Rudy W. Bilous, Donal O’Donoghue, Armin Scherhag, Ulrich Burger, Fernando de Alvaro. (2007) Target Level for Hemoglobin Correction in Patients With Diabetes and CKD: Primary Results of the Anemia Correction in Diabetes (ACORD) Study. American Journal of Kidney Diseases 49:2, 194-207
CrossRef473
Michael Fernandes, Hiroki Sawa, Giuseppe Bellini. (2007) Haemoglobin concentrations in chronic kidney disease. The Lancet 369:9559, 365
CrossRef474
Arintaya Phrommintikul, Steven Joseph Haas, Maros Elsik, Henry Krum. (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. The Lancet 369:9559, 381-388
CrossRef475
(2007) Journal Club. Kidney International 71:4, 288-289
CrossRef476
Giovanni FM Strippoli, Giovanni Tognoni, Sankar D Navaneethan, Antonio Nicolucci, Jonathan C Craig. (2007) Haemoglobin targets: we were wrong, time to move on. The Lancet 369:9559, 346-350
CrossRef477
Merlin C Thomas. (2007) Anemia in diabetes: marker or mediator of microvascular disease?. Nature Clinical Practice Nephrology 3:1, 20-30
CrossRef478
V. Prasad. (2007) Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. Yearbook of Medicine 2007, 215-217
CrossRef479
Barbara S. GILLESPIE, Jula K. INRIG, Lynda A. SZCZECH. (2007) Anemia management in chronic kidney disease. Hemodialysis International 11:1,
CrossRef480
David W. JOHNSON, Ann-Maree CRAVEN, Nicole Maree ISBEL. (2007) Modification of cardiovascular risk in hemodialysis patients: An evidence-based review. Hemodialysis International 11:1,
CrossRef481
2007. BIBLIOGRAPHIE GÉNÉRALE. , 259-272.
CrossRef482
Robert Steinbrook. (2006) Haemoglobin concentrations in chronic kidney disease. The Lancet 368:9554, 2191-2193
CrossRef483
Singh, Ajay K., Szczech, Lynda, Tang, Kezhen L., Barnhart, Huiman, Sapp, Shelly, Wolfson, Marsha, Reddan, Donal, . (2006) Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. New England Journal of Medicine 355:20, 2085-2098
Full Text484
Remuzzi, Giuseppe, Ingelfinger, Julie R., . (2006) Correction of Anemia — Payoffs and Problems. New England Journal of Medicine 355:20, 2144-2146
Full Text
- Letters
